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Abstract
Colorectal cancer (CRC) is the third most common diagnosed cancer in both women and
men in the United States. The gradual increase of incidence of second primary cancer
(SPC) among CRC individuals has been a concern in recent times. Many CRC survivals
have been forced back to be hospitalized for life-threatening cancers that are
nonmetastatic cancers of CRC. Literature has suggested that there may be a relationship
between metabolic syndrome (MetS) and CRC cases. The importance of early
surveillance, detection, and treatment of SPC in CRC patients is significant to achieve
better survival rates. The aim of this retrospective quantitative study was to investigate
the association between MetS and its components (hypertension, obesity, diabetes,
dyslipidemia, hypertriglyceridemia) and SPC among CRC patients, controlled for gender,
age, and race/ethnicity. Social cognitive theory was the theoretical framework of the
study. The 2011-2013 SEER-Medicare secondary data were used for this study and
included 4,217 CRC patients. Bivariate and multivariable analyses were conducted to
address this study’s aim. Results revealed that CRC patients who were aged 65 to 75
years (OR = 2.9, 95% CI: 2.2-3.8) and obese (OR = 6.5, 95% CI: 5.2-8.3) had
significantly more odds to develop SPC. This study promotes positive social change by
enhancing clinicians’ and public health policy makers’ understanding of the relationship
between age, obesity-induced MetS, and SPC in CRC patients. This study can also
highlight the need for the early introduction of a surveillance program for the detection of
SPC in CRC survivors by health care and public health professionals, and it demonstrates
the importance of early intervention in mitigating SPC morbidity and mortality rates.
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Chapter 1: Introduction to the Study
In this study, I aimed to examine if there is any association between metabolic
syndrome (MetS) and second primary cancers (SPCs) in colorectal cancer (CRC)
individuals. Emerging evidence is showing that CRC survivors are at risk of developing
SPCs (Lee et al., 2015; Raj, Taylor, Wray, Stamos, & Jason, 2011). SPCs cause remains
unclear in the United States (Raj et al., 2014). Previous research has implicated MetS as
the cause of CRC through different mechanisms in the literature like obesity, abnormal
blood lipid, Type 2 diabetes mellitus, inflammation, and hypoxia (Braun, Bitton-Worm,
& LeRoith, 2011). In this study, I explored the potential association of MetS with SPCs
in CRC survivors to understand why CRC survivors may be at high risk of developing
SPCs.
Previous researchers have found that there is high prevalence of MetS (mostly due
to obesity) among women CRC survivors (Oritz-Mendoza & De la Fuente-Vera, 2014).
Hence, there is need to study this association to have a more clear perspective of the risk
CRC survivors are exposed to and advise policy makers accordingly.
This study can help clinicians, public health, and policy makers to decide if there
is a significant risk among CRC survivors to develop SPC due to MetS. A high-risk
association will require adopting new surveillance, and prompt screening of SPC for
early detection and intervention can enhance survival and lead to social change.
The subsequent section includes the problem statement, which elucidates more
about the problem and provides more literature in support; the research questions section,
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which provides the independent and dependent variables in the study and the hypothesis;
and the theoretical framework for the study.
Background
MetS is a combination of conditions that can enhance the development of chronic
diseases. The mechanism of adipose tissue hypoxia in the obese individual is implicated
in the significant relative risk of incidence of CRC in obese individuals, even after
modifying for factors like smoking, body mass index (BMI), exercise, family history,
smoking, hormonelike insulin and insulin growth factors, aspirin intake, and red meat
consumption (Braun, Bitton-Worm, & LeRoith, 2011; Hu et al., 1999). Waist
circumference was more significantly predictive for CRC than the BMI (Braun et al.,
2011). Recently, the risk of development of SPCs after a CRC is rising among CRC
survivors (Dasgupta, Youlden, & Baade, 2012). The risk of being diagnosed with SPCs
was 33% higher (95% CI 1.12-1.56) for surgically treated patients and 45% higher (95%
CI 1.29-1.64) in patients with proximal colon cancers than in patients with rectal cancers
(Dasgupta et al., 2012). These SPCs are lung, bladder, kidney, stomach, and endometria
cancers. The risk of SPCs after CRC differed by anatomic site of the CRC, and it was
particularly pronounced in those whose CRC was in the transverse to descending colon
(Phipps, Chan, & Ogino, 2013). There are limited studies on SPCs in the United States,
and there is a need for patient education and effective surveillance programs for SPCs
(Lee et al., 2015; Noura et al., 2009). There is a significant risk of MetS among obese
CRC survivors with SPC (Oritz-Mendoza & De la Fuente-Vera, 2014). The present study
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can help fill the gap in knowledge in public health and surgery on the association
between MetS and SPC in CRC survivors in the United States.
The study is needed to allow policymakers and clinicians to have a new approach
to SPC management in CRC survivors through intervention and surveillance that could
reduce mortality of CRC survivors.
Problem Statement
CRC is the third most common cancer and the third highest cause of cancer
mortality in the United States (Haggar & Boushey, 2009; Siegel, Desantis, & Jemal,
2014). Increasing incidence of SPC has been noted among CRC patients. A person
diagnosed with CRC has an increased risk of developing SPC (SIR: 1.4; 95% CI: 1.3-1.5)
in relation to the general population (Enblad, 1990; Lee et al., 2015; Raj et al., 2011).
CRC has been associated with SPCs like lung (14%), bladder (11%), kidney (42%),
stomach (28%), and endometrial cancers (26%; Phipps et al., 2013). Although the degree
of risk is uncertain (Raj et al., 2011), the risk for SPCs has been found to increase among
CRC patients irrespective of whether a curative surgery was done or not (Lee et al., 2015,
Noura et al., 2009). The occurrence of SPCs in CRC patients is supported by the
emerging hypothesis that there could be an association between MetS and some cancers
(Esposito, Chiodini, Colao, Lenzi, & Giugliano, 2012). MetS and its component diseases
are known as worldwide sources of health problems (Braun et al., 2011). MetS has five
components: hypertension, obesity (abdominal), hypertriglyceridemia, dyslipidemia, and
diabetes (Braun et al., 2011). The presence of any three of these components is
confirmatory of MetS. The rise in SPCs affects men and women of different races mainly
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in those 40 to 79 years of age. The individuals with the highest incidence of SPCs are
those with CRC who are either undergoing treatment for CRC or are survivors of CRC.
The increase in cancer has also been described in individuals without CRC but who have
certain components of MetS in addition to other factors like inflammation and hypoxia
(Braun et al., 2011). MetS currently affects one-third of U.S. adults (Kanagasabai, Nie,
Mason, & Ardern, 2014). Obesity has been associated with CRC (Braun et al., 2011;
Maet al. 2013). More than one-third (36.5%) of U.S. adults have obesity with age,
gender, and race disparity, putting them at increased risk for CRC and SPCs (Centers for
Disease Control and Prevention [CDC], 2016; Lee et al. 2015). Metabolic abnormality
using obesity and diabetes for an independent assessment of obesity and diabetes has
been described to have increased the incidence of CRC (Sturmer, Buring, Gaziano, &
Glynn, 2006).
A study conducted in Australia showed that the length of survival for CRC
patients with an SPC could be as little as 2 months (Dasqupta, Youlden, & Baade, 2012).
MetS through its components (hypertension, abdominal obesity, diabetes, high serum
triglycerides, low high-density lipoprotein [HDL] levels) is used as an index of predicting
a long term chronic problem like CRC development due to the increasing
acknowledgment of its role in enhancing not only cardiovascular disease but also chronic
diseases like colorectal adenoma, gastric, and colorectal cancer (Pais et al., 2009;
Pothiwala, Jain, & Yaturu, 2009; Trabulo et al., 2015). The component of MetS like waist
circumference and waist to hip ratio, both regarded as abdominal obesity, has a CRC risk
association (Trabulo et al., 2015) and the role of MetS in SPC development among
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individuals with CRC needs further investigation. There are a limited number of studies
in the United States on SPCs in CRC patients and on the association between MetS and
SPCs in individuals with CRC. Most of the previous studies on SPCs in CRC patients
have been done in Southeast England (Evans et al., 2002), Taiwan (Lee et al., 2015),
Queensland, Australia (Dasgupta et al,, 2012), and Mexico (Ortiz-Mendoza & De la
Fuente-Vera, 2014). Ortiz-Mendoza and De la Fuente-Vera (2014) discovered that there
is an association between MetS and SPC among female CRC survivors. The authors
studied 107 female participants between the age of 50 and 70 years, with a BMI of 25 to
37kg/m2. The mean glucose level for all the participants was 120 ± 58 mg/dL, cholesterol
228 ± 43 mg/dL, and triglycerides 207 ± 120 mg/dL. Fifty-five (51%) with glucose > 99
mg/dL, 85 (79%) with cholesterol > 199 mg/dL, and 67 (63%) with triglycerides > 149
mg/dL. Obesity (BMI = 30 kg/m2) occurred in 49 (46%) and metabolic syndrome in 27
(26%). The authors observed the high prevalence of obesity and concluded that it
accounted for the several components of MetS found in the study participants (OrtizMendoza & De la Fuente-Vera, 2014). In this study, I examined SPCs in CRC patients in
the United States and thus helped to fill this gap.
Purpose of the Study
The purpose of this quantitative study was to determine whether there is an
association between the components of MetS (increased blood pressure [greater than
130/85 mmHg], high blood sugar levels [insulin resistance], excess fat around the waist,
high triglyceride levels, low levels of good cholesterol, or HDL; independent variables)
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and SPCs (dependent variable) in CRC patients of different ages, gender, and ethnicity
(age, gender, and ethnicity are also independent variables).
Research Questions and Hypotheses
Research Question (RQ)1: Is there an association between hypertension and SPCs
in CRC patients?
H01: There is no association between hypertension and SPCs in CRC patients.
Ha1: There is an association between hypertension and SPCs in CRC patients.
RQ2: Is there an association between abdominal obesity and SPCs in CRC
patients?
H02: There is no association between abdominal obesity and SPCs in CRC
patients.
Ha2: There is an association between abdominal obesity and SPCs in CRC
patients.
RQ3: Is there an association between dyslipidemia and SPCs in CRC patients?
H03: There is no association between dyslipidemia and SPCs in CRC patients.
Ha3: There is an association between dyslipidemia and SPCs in CRC patients.
RQ4: Is there an association between diabetes and SPCs in CRC patients?
H04: There is no association between diabetes and SPCs in CRC patients.
Ha4: There is an association between diabetes and SPCs in CRC patients.
RQ5: Is there an association between hypertriglyceridemia and SPCs in CRC
patients?
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H05: There is no association between hypertriglyceridemia and SPCs in CRC
patients.
Ha5: There is an association between hypertriglyceridemia and SPCs in CRC
patients.
RQ6: Is there an association between age, gender, and ethnicity with SPCs in
CRC patients?
H06: There is no association between age, gender, and ethnicity and SPCs in CRC
patients.
Ha6: There is an association between age, gender, and ethnicity and SPCs in CRC
patients.
RQ7: Is there an association between MetS and SPCs in CRC patients?
H07: There is no association between MetS and SPCs in CRC patients.
Ha7: There is an association between MetS and SPCs in CRC patients.
Theoretical Foundation
Social cognitive theory (SCT) is a form of reciprocal determinism described by
Bandura in 1960 as an interpersonal level theory that describes the triangular dynamic
interrelationship between people (personal factors), their behavior, and their
environments. This theory started as a social learning theory but gradually developed into
SCT in 1986. SCT posits how people gain and keep some behavioral patterns while
giving the basis for intervention strategies (Bandura, 1977). SCT deals more with social
influence and external and internal social reinforcement (LaMorte, 2016). SCT examines
how individuals get and keep behavior as well as the social environment where the
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behavior is executed considering the individual’s previous experience, which determines
if a change will occur. It is this experience that affects reinforcements, expectations, and
expectancies that together determine the reason and if the individual will perform the
behavior (LaMorte, 2016). LaMorte (2016) explained that SCT started originally with
five constructs before self-efficacy was added to become SCT and has the following
constructs:
1. Reciprocal determinism: The core concept of SCT that refers to the triadic
dynamic and mutual interaction existing between the person (learned
experiences), environment (external system), and behavior (responses to
stimuli to achieve goals).
2. Behavioral capability: Proficiency to be able to use knowledge and skill to
perform a behavior after providing information on what to do. The individual
should know how to do it and so learn from the action of their behavior that
affects their environment.
3. Observational learning: The form of behavioral modeling that challenges the
individual's ability to watch a behavior in others to reproduce the action.
4. Reinforcements: The reaction to a person's internal or external responses that
determine if the action will be continued or not. Reinforcements are closely
associated with the reciprocal relationship between behavior and environment
and can be individually or environmentally initiated and can be positive or
negative.
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5. Expectations: Refers to the expected effect of an individual's behavior and can
be outcome expectations that can or cannot be health related. This expected
effect of an action can affect the completion of the behavior because people
expect the result of their action.
Expectancy- put attention on the value of the outcome. It is subjective.
Both expectations and expectancies originate from previous experience.
6. Self-efficacy: This refers to individual's personal ability to carry out a behavior
and is affected by the person's specific capabilities, other individual's factors, and the
environmental factors.
SCT is useful in achieving successful behavior change, especially in obesity,
which is the reason it is of importance in this study. There is an associated high relapse
rate, and it requires motivation, self-efficacy, and self-regulation (Teixeira et al., 2015).
In SCT, the individual is involved, the environment and the behavior. Using the construct
of SCT, an individual has to have the behavioral capability to know how to use
knowledge and skill to perform a behavior after providing information on what to do.
This is followed by observational learning, where the watched behavior is copied and
reproduced. If, for example, the exercise is skipping rope for 30 minutes every day while
counting numbers to 100, the individual should be able to reproduce the behavior. It is
after this that reinforcement reaction sets in as a response to the individual's personal
internal or external response that decides whether the action will continue. This action
can make or mar the theory. This phase is guided by the expectation of the individual,
which is based on the prior action. The positive outcome means the individual can
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continue without external regulation. The last construct is self-efficacy, which enables the
individual to continue skipping daily every morning for 30 minutes in order to obtain the
desired of health weight with subsequent improve weight, healthy heart, and better BMI.
This is an example of how social cognitive theory can be used in this study.
Conceptual Framework
The conceptual framework of this study was based on previous empirical studies
on how MetS is associated with colorectal cancer, which is a worldwide disease with
varying geographical distribution. MetS has been identified among many cancer
survivors, and its pathophysiology is described in the literature (De Haas et al., 2010).
Obesity and other MetS components have been described in Mexican women cancer
survivors (Ortiz-Mendoza & De la Fuente-Vera, 2014). The high prevalence of obesity
among Mexican women has accounted for the components of MetS observed among
cancer survivors in the study (Ortiz-Mendoza & De la Fuente-Vera, 2014). The influence
of MetS on women's SPCs provides ample evidence supporting that MetS is a risk factor
for many primary malignancies like CRC (Ortiz-Mendoza & De la Fuente-Vera, 2014).
Obesity or excessive body weight gain (apple shape), a component of MetS, has been
described in cancer pathogenesis. In the United States, 66% of the adult population is
obese with a BMI > 25kg/m2, and half of them have a BMI > 30kg/m2 (Braun et al.,
2011). Studies have revealed that fat tissue is a source of hormones like estrogen,
testosterone, and growth factors that favor cancer growth by modulating the effects of
diet and physical activity. The larger the effect of these factors, the higher the risk of
developing CRC (Hemminki, Li, & Gong, 2001). Abdominal circumference has been
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implicated as a better predictor of cancer than BMI in MetS patients. Obesity is a known
risk factor for many cancers, including breast, endometrial, colorectal, uterine, kidney,
pancreatic, and esophageal (Larsson & Wolk, 2007). It has been reported that obesity
could cause Type 2 diabetes mellitus, which is another strong factor in the pathogenesis
of certain cancers like CRC (Braun et al., 2011). The mechanism proposed has been the
development of hypoxia by adipose tissue due to the combination of obesity,
inflammation, and insulin resistance in patients with MetS due to adipose tissue
hypoxemia (Brauns et al., 2011). Obese individuals have chronic inflamed adipose tissue
due to high levels of inflammatory cytokines in plasma and adipose tissue, macrophage
infiltration, and activation in the adipose tissue. Furthermore, inflammation through
tumor necrotic factor can cause insulin resistance by mediating in the intracellular
signaling cascade of insulin (Ye, 2009). The high free fatty acids and decreased
adiponectin levels in the blood of obese people enhance insulin resistance (Braun et al.,
2011). This accounts for the pathogenesis of MetS and reveals a high relative risk for
colorectal cancer in obese people (Calle, Rodriguez, Walker-Thurmond, & Thun, 2003).
The empirical data on the known mechanisms of obesity-related MetS carcinogenesis and
the published differing impacts of MetS in different age groups, genders, as well as
various ethnicities, provided the framework for the choice of variables and the research
questions used in this study.
Nature of Study
This was a quantitative retrospective cohort study using secondary data. I used
two cohorts. One cohort had CRC but not SPCs, and the second cohort had both. In this

12
study, the characteristics of the study population were described, and I attempted to
identify risk factors for CRC and SPCs among CRC patients. The research questions
were intended to identify the role played by age, gender, ethnicity, and MetS components
(independent variables) in the pathogenesis of SPCs among CRC patients (dependent
variable). The relationship between the dependent and independent variables was
analyzed using bivariate and regression analysis via SPSS v25. Logistic regression helped
to ascertain the odds ratios and the probabilities of association.
Types and Sources of Data
The secondary data derived from Surveillance, Epidemiology, and End Results
(SEER) cancer registries 2011 to 2013. Patients with a history of CRC, aged > 65 years,
with no history of cancer prior to their CRC diagnosis were eligible for the study.
Patients who were followed < 1 year and/or had their SPCs diagnosed within the first
year after diagnosis of CRC were not included due to difficulty in differentiating
synchronous from metachronous SPCs in CRC patients. Moreover, patients with cancer
of the small intestine were excluded to avoid misclassification due to difficulty in
distinguishing it from SPCs in the first year (see Lee et al., 2015).
Operational Definitions
In this study, the following definitions apply:
Colorectal cancer (CRC): The primary cancer of this study with anatomical
location in the colon (ascending, transverse, descending, and sigmoid) and rectum
depending on where it starts.
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Metabolic syndrome (MetS): Refers to a group of risk factors that when presented
together in a person can cause cardiovascular disease, stroke, and chronic diseases. These
risk factors include increased blood pressure (greater than 130/85 mmHg), high blood
sugar levels (insulin resistance), excess fat around the waist, high triglyceride levels, and
low levels of good cholesterol, or HDL (Braun et al., 2011).
Metachronous SPC: SPC detected after 6 months of the initial primary cancer
diagnosis (Li-Chu et al., 2014; Lopez et al., 2009).
Second primary cancer (SPC): For this study, SPC represents the cancer that
develops not as metastases of the primary cancer (CRC) but of a different histological
cancer type arising after the diagnosis of primary cancer (CRC). SPCs for this study
included lung, stomach, bladder, kidney and endometrial cancers (see Lee et al., 2015).
Synchronous SPC: SPC detected within 6 months of the initial primary cancer
diagnosis (Li-Chu et al., 2014; Lopez et al., 2009).
Assumptions
An assumption was that the dataset contained correct diagnoses of SPCs in CRC,
age, gender, and ethnicity. I assumed that the SPC dataset population was representative
of the population, but results may not be generalizable to other populations. This is
secondary dataset, which made it difficult to verify information in the dataset obtained
from the study group.
Scope and Delimitations
The research problem was about if there is any association of MetS with the
development of SPCs in CRC patients using various associated components of MetS and
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age, gender, and ethnicity as independent variables. The study population included
participants with CRC without SPCs and those with SPCs with CRC of ages above 40
years to exclude CRC of familial origin. The inclusion criteria were that of primary
cancer histologically confirmed to be CRC, and metastatic lesion from elsewhere had to
be excluded (Evans et al., 2002; Li-Chu et al., 2014). I excluded SPCs occurring within 6
months of diagnosis of CRC for lack of differentiation that can lead to misdiagnosis of
metastases as SPCs (see Yen et al., 2015). There is a limitation based on the available
data in the dataset because the study was limited by the number of the participants in the
dataset who were eligible to be included in the study.
Limitations
The source of the sample population in a secondary data analysis may lead to bias
in the study and, therefore, was limited to the data available in the dataset. The data were
limited due to rare screening for SPC as described in the study and data availability. It
was not possible to obtain additional information about the subjects in the cohorts.
Consequently, analyses of relationships among variables were limited by what
information was collected originally due to lack of access to additional information about
the subjects in the cohorts. In other to address limitations, the source of the dataset was
verified to be credible and reliable by checking where it was published(see Center for
Public Education, 2017). The source of funding for the collection and analysis of data
could be another method for checking for credible and reliable data sources, especially
because it is possible that the organization that publishes the data may not have a
particular bias, but the organization that funded the data collection could. Another way to
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check for credible and reliable data source is to use the Stanford guidelines for web
credibility (see Center for Public Education, 2017):
•

Websites should have verifiable reference checks.

•

The author should be identifiable as well as affiliates, credentials, and
contact information.

•

The site owner’s or managing party physical address and contact
information should be included.

•

The site mission statement and identification of staff responsible for the
site should be indicated

•

Is there site advertisement? What is the source of funding even if its
managed by a not-for-profit organization?

•

What is the site quality and outlook? Is the site professional in
appearance?

•

How often is the site update? Are there typographical and grammatical
errors?
Significance of the Study

The complex nature of cancer pathogenesis, including the detailed roles of
oncogenes and tumor suppressors, suggests that many factors play a key role in cellular
metabolism (Boroughs & DeBerardinis, 2015). The recent shift in thinking over the past
5 years is that cancer is a metabolic disorder rather than a genetic disease (Wishart,
2015). The authors in a study conducted in Mexico concluded that MetS may be a risk
factor for a SPC in women (Ortiz-Mendoza, Pérez-Chávez, & De-la Fuente-Vera, 2016).
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This study can provide insight as to the role MetS plays in SPCs associated with CRC. A
combination of CRC with any of the SPCs creates a higher risk of mortality for the
patient, thus necessitating closer surveillance for SPCs in all CRC patients. It is
imperative to determine if there is an association between MetS and SPCs in CRC
patients as this can help clinicians and policy makers to decide if there is need to adopt
surveillance in CRC patients that can enhance the selection of individuals who may
benefit from tertiary prevention and reinforce the importance of primary prevention.
Social Change Implications
This study can enhance clinicians and public health policy maker’s understanding
of the relationship between MetS and SPCs in CRC patients. This study can promote the
need for an early introduction of a surveillance program for detection of SPCs in CRC
survivors by clinicians and public health policy makers and show the importance of early
intervention in mitigating morbidity and mortality rate, thereby enhancing survival.
The importance of early detection of these SPCs in CRC patients cannot be
underestimated, as ignoring the presence and effect of SPCs can adversely affect the
prognosis, treatment, and recovery. The results of the current study can be disseminated
to clinicians and public health policy makers to promote screening for SPCs individuals
with CRC.
Summary
CRC is the second common cause of death in the United States (Haggar &
Boushey, 2009; Siegel et al., 2014). The discovery of MetS and its association with
chronic diseases like CRC is a public health marker for more efficient screening and
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preventive measures to detect at-risk individuals by controlling the components of MetS.
MetS currently affects one-third of U.S. adults (Kanagasabai et al., 2014) and has been
described to promote many cancers in obese cancer survivors (Ortiz-Mendoza & De La
Fuente-Vera, 2014). A diagnosis of CRC puts the individual in jeopardy of developing
SPCs like lung, bladder, stomach, kidney, and endometrial cancers (Lee et al., 2015; Raj
et al., 2011). Some studies have described SPCs regarding a predisposition to the primary
cancer sites and location of cancer in the colon (Phipps et al., 2013) while others have
described SPCs about age and gender (Siegel et al., 2014). One study conducted in
Mexico described a possible association between MetS and SPC in obese women who are
cancer survivors (Ortiz-Mendoza & De la Fuente-Vera, 2014). To the best of my
knowledge, no researcher has examined the association of MetS and ethnicity as a risk
factor for developing a second primary lung, endometrial, kidney, stomach, and bladder
cancer in patients previously diagnosed with CRC cancer using multivariable analysis.
Chapter 2 contains a review of the current literature on MetS and CRC cancer
epidemiology SPCs and the pathology, diagnosis, and prognosis of lung, bladder,
stomach, endometrial, and kidney cancers. In Chapter 2, studies supporting the
conceptual framework and study design are presented. An in-depth revision of
nonmodifiable risk factors of age, ethnicity, and gender are addressed as well as
modifiable risk factors such as lifestyle (diet) and obesity.
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Chapter 2: Literature Review
Introduction
The individuals diagnosed with CRC have an increased risk of developing SPC
(SIR: 1.4; 95% CI: 1.3-1.5) compared to the general population (Enblad 1990; Lee et al.,
2015; Raj et al., 2011). This risk is increasing among CRC survivors irrespective of the
administration of the curative surgical therapy (Lee et al., 2015; Noura et al., 2009). An
emerging hypothesis supports the existence of a possible association between MetS and
certain cancers like CRC (Esposito et al., 2012). MetS affects one-third of U.S. adults
(Kanagasabai et al., 2014). There are five components of MetS: hypertension, obesity
(abdominal), hypertriglyceridemia, dyslipidemia, and diabetes, and only three are
required for confirmation of MetS (Braun et al., 2011). This problem of SPC affects
individuals of 40 to 79 years, both male and females of different races, with the highest
incidence of SPCs among those with CRC on treatment or survivors of CRC (Lee et al.,
2015, Noura et al., 2009). Obesity, a part of MetS, has been associated with increased
incidence of CRC (Braun et al., 2011). Limited studies exist in the United States on SPC
in CRC patients.
This study can fill the gap in the literature by examining the association between
MetS and SPC among CRC survivors. A quantitative research methodology was applied
using secondary data set to answer the research questions and hypotheses.
This chapter includes a description of the epidemiology of colorectal cancer in the
United States. It also includes CRC risk factors, metastases, morphology and histological
grading and classification, tumor marker and screening, staging, and treatment. Literature
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on SPC with the risk factors and an in-depth update on metabolic syndrome with its
components, and its role in the pathogenesis of cancer are also discussed.
The purpose of this quantitative study was to determine whether there is an
association between the components of MetS and SPCs in CRC patients of different ages,
gender, and ethnicity.
Literature Search Strategy
I employed MEDLINE, National Cancer Institute Comprehensive, CINAHL,
PUBMED, GOOGLE SCHOLAR, and Walden University dissertation ProQuest to
conduct this literature review. During the search, I used the following major terms:
metabolic syndrome, colorectal cancer, epidemiology, diagnosis, second primary cancers
of colorectal cancer, colon cancer, endometrial cancer, lung cancer, kidney cancer,
bladder cancer, colorectal cancer treatment, prognosis, age, gender, ethnicity, and CRP.
The above search method produced peer-reviewed articles from 2010 to 2020, among
other articles.
Conceptual Framework
The conceptual framework chosen for this study was based on previous empirical
studies on how MetS are associated with colorectal cancer and SPC. The incidence of
CRC survivors is increasing, and so is the risk of developing SPC (Guan et al., 2015).
MetS has been identified among many cancer survivors, and its pathophysiology is
described in the literature (De Haas et al., 2010). Obesity and other MetS components
have been described among Mexican women cancer survivors to be contributory to the
risk of developing SPC (Ortiz-Mendoza & De la Fuente-Vera, 2014). The high
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prevalence of obesity among Mexican women population has accounted for the MetS
observed among cancer survivors in the study (Ortiz-Mendoza & De la Fuente-Vera,
2014). The influence of MetS on cancer survivors provides ample evidence supporting
that MetS is a risk factor for many primary malignancies like CRC (Ortiz-Mendoza & De
la Fuente-Vera, 2014).
Obesity has been described in cancer pathogenesis. In the United States, 66% of
the adult population is obese, with a BMI > 25kg/m2, and half of them have a BMI >
30kg/m2 (Braun et al. 2011). Studies have shown that fat tissue is a source of hormones
like estrogen, testosterone, and growth factors that favor cancer growth by modulating the
effects of diet and physical activity. The larger the effect of these factors, the higher the
risk of developing CRC (Hemminki et al., 2001). Abdominal circumference has been
implicated as a better predictor of cancer than BMI in MetS patients. Obesity is a known
risk factor for many cancers, including breast, endometrial, colorectal, uterine, kidney,
pancreatic, and esophageal (Larsson & Wolk, 2007). It has been reported that obesity
could cause Type 2 diabetes mellitus, which is another strong factor in the pathogenesis
of certain cancers like CRC (Braun et al., 2011). The mechanism proposed has been the
development of hypoxia by adipose tissue due to the combination of obesity,
inflammation, and insulin resistance in patients with MetS due to adipose tissue
hypoxemia (Brauns et al., 2011).
Obese individuals have chronic inflamed adipose tissue due to high levels of
inflammatory cytokines in plasma and adipose tissue, macrophage infiltration, and
activation in the adipose tissue. Furthermore, inflammation through tumor necrotic factor
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can cause insulin resistance by mediating in the intracellular signaling cascade of insulin
(Ye, 2009). The high free fatty acids and decreased adiponectin levels in the blood of
obese people enhance insulin resistance (Braun et al., 2011). This account for the
pathogenesis of MetS has revealed a high relative risk for colorectal cancer in obese
people (Calle et al., 2003). Furthermore, obesity has been linked to MetS and insulin
resistance in young adults with middle incomes (Madeira et al., 2013). The empirical data
on the known mechanisms of obesity-related MetS carcinogenesis and the published
differing impacts of MetS in different age groups, genders, as well as various ethnicities,
provided the framework for the choice of variables and the research questions used in this
study.
Recent study has revealed that the presence of obesity and MetS in early CRC is
associated with worse survival prognosis (Cespedes-Feliciano et al., 2016).
Ortiz-Mendoza et al. (2016) observed from their study that obesity among
Mexican women who have survived previous CRC is a predisposing risk factor for
developing SPC. The study was a case-control study, using nine cases and 27 controls
from a general hospital in Mexico City. The participants were women having second
cancers (cases) age-matched with women with only one neoplasm as controls.
Anthropometry measurements were taken for blood pressure, blood glucose,
triglycerides, height, and weight to calculate the BMI and tumor type, and total
cholesterol was obtained from their medical files. The criteria for selecting participants
was the development of second cancer at least 6 months after the diagnosis of the first
tumor. Diabetes mellitus was diagnosed if the individual was on insulin or an oral

22
hypoglycemic agent or if the fasting serum glucose was 126 mg/dl or greater.
Hypertension was diagnosed using antihypertensive or having blood pressure
135/85mmhg or higher. Dyslipidemia was diagnosed using fibrates, statins, or having a
cholesterol level greater than 199mg/dl or glyceride values greater than 149mg/dl. The
diagnosis of the modified metabolic syndrome is made when three of the criteria are
present, as previously highlighted. The sample size was calculated, and statistical analysis
was done using Pearson “χ2” and Fischer’s test, and the odd ratio was used to study the
association strength between variables using a 95% CI, and p < 0.05 was regarded as
significant.
Lee et al. (2015) studied the features of second primary cancer in individuals with
previous colorectal cancer among Taiwan’s population. This was a multivariate
retrospective cohort study conducted over a 16-year study period, using data from
Taiwan’s National Health Insurance research database. Out of 98,876 CRC patients in the
study period, including 55,729 (56.4%) men and 43,147 (43.6%) women, with a median
age of 67 years, 4,259 had developed SPCs after a median follow-up of 4.03 years. Data
extraction and computing were done using Perl programming language (Version 5.12.2),
the Microsoft SQL Server 2012 (Microsoft Corp., Redmond, WA) for data linkage and
processing, and SAS 9.2 software for analysis. The standard incidence ratio (SIR) of the
SPC was 1.13 (95% CI = 1.10-1,17) using a Poisson probability distribution. Univariate
and multivariate Cox proportional hazards models were used to identify predictors of
SPC occurrences among CRC patients.
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When compared with the general population, colon cancer had a higher incidence
of ovarian, thyroid, prostate, and hematologic cancers, whereas rectal cancer had a high
risk of bone and soft tissue cancers (Lee et al., 2015). Colon and rectal cancer had a
significantly higher risk for lung, kidney, breast, uterine, and bladder cancers than the
general population (Lee et al., 2015). A reduced risk was noticed for liver and biliary
tract cancers with rectal cancer (Lee et al., 2015). An independent risk factor from the
study for SPC includes age of 70 and above, men, chronic obstructive pulmonary disease
(COPD), cirrhosis, and dyslipidemia (Lee et al., 2015). CRC survivors, therefore, have
increased risk of developing SPC.
Youlden and Baade (2011) studied the relative risk of developing any SPC in
Queensland, Australia using a retrospective cohort study. The dataset was obtained from
the Queensland Cancer Registry. The population included participants 15 years and older
with a 2-month history of previous first primary invasive cancer. A total of 204,962 had
first primary cancer, and 23,580 had SPC over a follow-up period of 5 to 25 years. The
author excluded synchronous primary cancers within 2 months of the first primary
cancer, and third cancers were also not included. The various cancers of the body sites
were analyzed as cancers of head and neck, cancers of colon and rectum, and others body
cancers were classified as “other.” The SIR was calculated by dividing the total observed
cases of second primary cancer by the expected number to estimate the risk of a cancer
patient developing a second primary cancer relative to the incidence of cancer among the
general population. The Poisson distribution was used to deduct the CIs used for the SIRs
using 95% level of certainty, and SAS v9.2 for Windows was used for analysis. The
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authors concluded that the highest percentage of second primary cancers occurred after
an initial diagnosis of melanoma (21.6%), colorectal cancer (12.9%), prostate cancer
(12.7%), or female breast cancer (12.6%). There are significantly increased relative risks
of invasive cancer for males after the diagnosis of head and neck cancer, lung cancer,
kidney cancer, esophageal cancer, melanoma, bladder cancer, non-Hodgkins lymphoma,
thyroid cancer, lymphoid leukemia, or myeloid leukemia. However, males with the
primary diagnosis of either prostate or stomach cancer had a significantly lower risk of
cancer compared to the general population. The female cohort had a higher relative risk
for second cancer for those diagnosed with head and neck cancer, colorectal cancer,
cervical cancer, lung cancer, kidney cancer, melanoma, breast cancer, uterine cancer,
bladder cancer, non-Hodgkins lymphoma, thyroid cancer, lymphoid leukemia, or myeloid
leukemia. The female survivor had no significantly lower risk of developing a second
invasive cancer in relation to the general population.
Literature Review
Colorectal cancer refers to any growth, lump or tumor of slowing growing in the
colon and rectum. CRC is the second most common cancer after lung cancer (Li-Chu et
al., 2014),). CRC affects men and women of all races and ethnic groups and mostly
common in 50 years and older (CDC, 2017) and CRC remain a burden in the United
States as 1,177,556 U.S. residents were estimated to be living with colorectal cancer in
2013 although the mortality rate has reduced as survival rate increases (Marley, & Nan,
2016).
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CRC can be sporadic while 5–10% are from inherited syndromes like the
hereditary non-polyposis colon cancer (HNPCC) and familial adenomatous polyposis
(FAP). It is not unusual to have some overlap of genetic abnormalities involving both
sporadic and inherited forms. The key mutation involved in colorectal carcinogenesis
include APC, KRAS, and p53 genes. The individual with first degree relative with CRC
has a risk of having colorectal cancer to be three times greater than one who has no
family history (George & Rockall, 2017).
The most common histopathology form of colorectal cancer is adenocarcinoma
which is postulated to have developed from the adenoma–carcinoma sequence which
includes a natural progression from benign polyps into invasive cancerous lesions
(George & Rockall, 2017).
CRC symptoms may not be detected on time for some time, and when it presents,
the symptom can be easily confused with other diseases like hemorrhoids, anal fissure
due to the similar characteristic presentation of blood in the stool (Eyvazzadeh & Reilly
Colon and Rectal Center, N.D). Occasionally, the blood may not be obvious to the naked
eye, and a test for occult blood on stool sample may be necessary. Another symptom
could be changed in bowel habit with an alternate presentation of constipation and
diarrhea. Other symptoms can appear as the disease advances. Symptoms may depend on
the location of cancer, right-sided cancer tends to bleed and cause diarrhea while left
sided cancer may not be detected early until it presents later with a bowel obstruction
(Dragovich, 2014).
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In advanced colon cancer cases, common clinical presentations include irondeficiency anemia, rectal bleeding, abdominal pain, change in bowel habits, and intestinal
obstruction or perforation (Toh, Griffiths & Farooq, 2012).
Abdominal symptoms like abdominal pain, vomiting, mucus discharge with stool
and feeling of incomplete emptiness of the rectum (otherwise called Tenesmus) (Mayo
Clinic, 2018). Other symptoms of CRC include fatigue, anemia, lack of appetite, rapid
weight loss and bowel obstruction (Mayo Clinic, 2018). Colorectal cancer can spread by
direct extension to adjacent structures and via lymphatics or blood (America Cancer
Society, 2018). The most frequently involved metastatic sites are the liver, regional
lymph nodes, lungs, and bones (Riihimaki, Hemminki, Sundquist & Hemminki 2016).
Epidemiology of CRC
The incidence rate is the most appropriate form of tracking the disease occurrence
and is not affected by changes in treatment and survival, but CRC incidence has been
affected by diagnostic techniques and screening program (Haggar & Boushey, 2009).
CRC account for 9% of all cancer incidence (Haggar & Boushey, 2009). The incidence of
CRC is decreasing in the United States and western countries due to improvement in
early detection, supportive care and treatments giving rise to increasing in survivors who
are developing second primary cancers (SPC) (Dasgupta, Youlden & Baade, 2012). CRC
has a wide geographical variation with incident cases of 9.4% of cancer in men and
10.1% in women although the distribution is not uniform globally (Haggar & Boushey,
2009). This geographic variation is based on the understanding that CRC is a disease of
developed western cultured countries although there could be under reporting of the
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disease among the developing countries (Haggar & Boushey, 2009). The incidence rate
of CRC between countries could varies up to 10 times from the highest rates to those with
the lowest rates and could be from more than 40 per 100,000 people in the United States,
Australia, New Zealand, and Western Europe to as low as below 5 per 100,000 in Africa
and some parts of Asia (Haggar & Boushey, 2009). Marley and Han (2016) reported that
only 2-8% of CRC was found in individual less than 40years in the United States and the
European Union whereas Egypt, Saudi Arabia, the Philippines, and Iran has rates of 38%,
21%, 17%, and 15-35%, respectively.
CRC represents the third deadliest cancer and remains a heavy burden on the US
population, as 1,177,556 U.S. residents were estimated to have been living with
colorectal cancer in 2013 (Marley & Nan, 2016). Over some decades the burden of CRC
has been reducing in both incidence and mortality rate while there is an improvement in
the 5-year survival rate from low of 49.8% to a high of 66.2% (Marley & Nan, 2016).
CRC survival depends a lot on the disease stage at the time of diagnosis. The
earlier the stage of cancer at diagnosis, the higher the chance of survival. The usual trend
is for CRC detected at localized stage to have 90% 5-years survival rate, 70% for CRC at
the regional stage and 10% for those with distance metastases (Haggar & Boushey,
2009).
Factors for CRC
There are 12 non-screening risk factors for CRC and these include family history
of CRC, physical activity, inflammatory bowel disease, body mass index, hormone
therapy in postmenopausal women, aspirin/nonsteroidal anti-inflammatory drug use, red
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meat, fruit cigarette smoking, and consumption of processed meat, vegetables, and
alcohol (Johnson et al., 2013).
Body Mass Index. There was found a significant association between BMI and
CRC (RR = 1.10 per 8 kg/m2, 95% CI: 1.08–1.12). The association between BMI and
CRC among males (for CRC, RR = 1.29 per 8 kg/m2, 95% CI: 1.26–1.34; for colon
cancer, RR = 1.53 per 8 kg/m2, 95% CI: 1.32–1.77) was stronger than the association for
females or the mixed population (for CRC, RR = 1.15 per 8 kg/m2, 95% CI: 0.98–1.34;
for colon cancer, RR = 1.27 per 8 kg/m2, 95% CI: 1.07–1.51) (Johnson et al., 2013).
Physical activity. Physical activity has a significant negative correlation with
CRC risk (RR = 0.88 per 2 standard scores, 95% CI: 0.86–0.91) but there was significant
heterogeneity (Q=146, p<0.0001) which could be due to the changes in study type
(cohort vs. case-control), cancer site (colon vs. CRC), and gender (female vs. male or
mixed population) (Johnson et al., 2013)”
Tobacco (cigarette smoking). Using 1966 colon cancer cases and 7433 CRC
cases in 15 studies to examine the association between tobacco use and CRC, there was a
lack of proof to support nonlinearity between smoking and CRC (p = 0.002) (Johnson et
al., 2013). Tobacco use was associated with the risk of development of CRC.
Alcohol. The author used data from 2469 colon cancer cases and 9717 CRC cases
in 22 studies to examine the role of alcohol in the development of CRC and concluded
that neither gender nor site of cancer was a significant source of variation. The overall
linear trend between alcohol consumption and CRC was not significant (RR = 1.06 per 5
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drinks/week, 95% CI: 0.91–1.23) and (RR = 1.26 per 20 drinks/week, 95% CI: 0.68–
2.32) (Johnson et al., 2013).
Family history. The authors studied the association between a history of CRC in
first-degree relatives and CRC risk using 8091 cases of CRC in 16 studies including
family history data. Six of the articles reported risk estimates for females only, and the
other ten articles reported risk estimates for a mixed population. The risk to develop CRC
in individuals with family history was higher for compared to those with no family
history of CRC (RR = 1.80, 95% CI: 1.61–2.02) (Johnson et al., 2013).
Inflammatory bowel disease (IBD). The author examined the association
between IBD and CRC risk using data from 44799 patients with IBD and findings of 582
CRC cases and 14 colon cancer cases in 13 cohort studies,11 of which reported risk
estimates for the male-female mixed population. Inflammatory bowel disease was
identified as a risk factor for CRC if left untreated (Johnson et al., 2013).
Postmenopausal hormone therapy (HT). The authors observed significant
heterogeneity (p = 0.04) and nonlinearity (p < 0.001) between current HT use and CRC,
using 765 colon cancer cases and 1441 CRC cases among current HT users and never
users, as reported in 7 studies. There may be reduced risk of CRC with HT because of the
low p value (Johnson et al., 2013).
In a study about the correlation between CRC risk and aspirin/NSAID use, there
was no statistical significance (Johnson, et al., 2013).
Processed meat. There was no statistically significant linear trend between
processed consumption and CRC (p = 0.28) (Johnson et al., 2013).
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Red meat. There was a significant positive correlation between CRC and red
meat consumption (RR=1.13 per 5 servings/wk, 95% CI: 1.09–1.16). A significant linear
dose-response relationship between the risk of colon cancer and red meat consumption
(p=0.006) was detected (Johnson et al., 2013).
Fruit. Fruit consumption has some evidence of nonlinearity (p=0.02) association
between fruit consumption and CRC (Johnson et al., 2013). There is a strong association
of fruit intake with reduced risk of developing CRC in both men and women (Lee, Shin,
Oh & Kim, 2017).
Vegetables. There is a significant inverse association between vegetable
consumption and CRC (RR = 0.94 per 2 servings/day, 95% CI: 0.91–0.98) and (RR =
0.86 per 5 servings/day, 95% CI: 0.78–0.94) (Johnson et al., 2013). Lee, Shin, Oh &
Kim, (2017), found that a high intake of vegetables reduces the risk of CRC.
Diagnosis of CRC. The diagnosis of CRC is done by colonoscopy examination, a
form of endoscopic examination that allows a visual view of the colorectal segment of the
large intestine and afford the clinician the opportunity to obtain suspected cancer biopsy
for histological laboratory examination (George & Rockall, 2017). The computed
tomography (CT) scan also be used for both diagnosis and evaluation of fistula and
abscess formation which may locally complicate the CRC. The CT could be used to
check for metastatic spread to organs like the liver or lungs (George & Rockall, 2017).
Metastases. CRC has the capability to metastases to extra intestinal sites like
liver, lungs, and peritoneum and recurrence are seen in the brain, peripheral lymph nodes,
bone, and thyroid gland (Augestad, Merok & Ignatovic, 2017). The mechanism by which
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this occurs is not fully understood despite decades of research studies (Augestad, Merok
& Ignatovic, 2017). There are metastases predictors such as sex, age, TNM stage, Tumor
morphology, histologic grade, Carcinoembryonic antigen levels, Lymph node harvest,
Tumor invasion in lymphatic and venous vessels, perineural invasion, and tumor location.
Sex. Male sex has a poor prognosis compared to the female sex. Also, men have
higher incidence rate but lower survival rate after curative surgery (Augestad, Merok &
Ignatovic, 2017).
Age. Age is regarded as an independent CRC risk factor with reduced survival
rate after curative surgery as the age increases (Widdison, Barnett & Betambeau, 2011).
Morphology. CRC are histologically mainly adenocarcinomas in origin, arising
from the glandular epithelium of the colon and rectum. Adenocarcinomas CRC has
histologic subtypes like mucinous adenocarcinoma (5%-15%) and signet ring cell tumors
(1%). Younger individual, advance stage cancer, poor outcome and lower survival rate
commonly found in signet ring cell adenocarcinoma compared to non-signet
adenocarcinoma CRC (Augestad, Merok & Ignatovic, 2017). However, its only in rectal
cancer that the Mucinous adenocarcinoma is also associated with young age and lower
survival rates, and there is no effect on survival in colon cancer (Augestad, Merok &
Ignatovic, 2017).
Histologic grade. The histologic grade and tumor differentiation are described by
TNM classification. The more differentiated a tumor, the slower growth and the spread
(American Cancer Society, 2017). When a tumor is well-differentiated, it is designated
as G1tumor, moderately differentiated tumors as G2 while a poorly and undifferentiated
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tumors are designated G3 and G4, respectively. The higher the tumor’s histologic grade,
the worse the prognosis than G1 and G2 tumors (Augestad, Merok & Ignatovic, 2017).
Lymph node harvest. The more the harvested lymph node, the higher the risk of
possible recurrence in both node positive and negative disease. There is associated
improved survival with the number of lymph node recovered. Individuals with less than
eight nodes have 62% for 5-year survival rate whereas those with more than 17 lymph
nodes had a 76% 5-year survival (Augestad, Merok & Ignatovic, 2017).
Tumor invasion in lymphatic and venous vessel. This represents the main route
of hematologic and lymphatic tumor metastases. This is dependent on the frequency of
the spread, a number of tumor blocks. The author found a positive association between
lymphatic invasion, tumor budding, depth of the tumor, poor differentiation, and lymph
node metastases but inconclusive effect on the survival rate. Venous invasion is found to
be associated with advanced T category and tumor depth and is regarded as an
independent prognostic marker of extra intestinal metastases and reduced survival
(Augestad, Merok & Ignatovic, 2017).
Perineural invasion. This is a new path, and it refers to the direct growth of
cancer into the perineum of autonomic nerves inside of the superior and inferior
mesenteric nerve plexus (Augestad, Merok & Ignatovic,2017).
Tumor location. Tumors of the right colon, left colon or rectum (Figure1) are the
risk factor for metastases and better survival outcome. The left colon has 70% chance of
having liver metastases while rectal cancer has over 200% of recurrence or develop lung
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metastases when compared to the right colon cancer (Augestad, Merok & Ignatovic,
2017).
Carcinoembryonic antigen. Carcinoembryonic antigen (CEA) is associated with
high preoperative levels which are indicative of risk of CRC recurrence. CEA has high
specificity but low sensitivity to detect CRC recurrence in isolation and could only be
used as a surveillance test (Augestad, Merok & Ignatovic, 2017).
Staging and imaging of colorectal cancer. The CRC cancer stage at diagnosis
during the presentation is the determinant factor for the outcome. CRC staging is based
on the international standard referred to as the TNM classification where T represents
Tumor, N is for lymph node, and M is for extra-intestinal metastases (George & Rockall,
2017). The prognosis of CRC is dependent on the invasiveness of the tumor (T), the
extent of regional lymph node (N) involvement and the presence of distant extraintestinal metastases (M). Hideki et al., (2012) emphasized that the TNM classification is
a reliable index for prognostic and better treatment plan for individuals having malignant
tumors.
Clinical staging is based on findings from colonoscopy, computed tomography
(CT) scan of the chest abdomen and pelvis and magnetic resonance imaging (MRI) scan
of the pelvis for rectal tumors (George & Rockall, 2017). Conflicting liver lesions may
need Ultrasound of MRI for assessment. Positron emission tomography (PET) scan may
also be helpful in determining sites of disseminated disease. Diagnosis is usually by
colonoscopy examination (George & Rockall, 2017).
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Wolpin and Mayer, (2008) presented the TNM Staging System for Colorectal
Cancer as follows:
Primary tumor (T)
Tx

Primary tumor cannot be assessed

Tis

Carcinoma in situ

T1

Tumor invades submucosa

T2

Tumor invades muscularis propia

T3

Tumor invades through the muscularis propria into the subserosa

T4

Tumor directly invades other organs or structures, or perforates visceral

Peritoneum
Regional lymph nodes (N)
Nx

Regional lymph nodes cannot be assessed

N0

No regional lymph node metastases

N1

Metastases in one to three regional lymph nodes

N2

Metastases in four or more regional lymph nodes

Distant metastases (M)
Mx

Presence or absence of distant metastases cannot be determined

M0

No distant metastases detected

M1

Distant metastases detected

Stage Grouping and Five-year Survival
Stage TNM classification
I T1–2, N0, M0

> 90 %

Five-year survival
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IIA

T3, N0, M0

80–85%

IIB

T4, N0, M0

70–80%

IIIA

T1–2, N1, M0

65–80 %

IIIB

T3–4, N1, M0

50–65 %

IIIC

T1–4, N2, M0

25–50 %

T1–4, N0–2, M1

5–8 %

IV

Wolpin & Mayer, (2008) reported TNM classification as the most frequently used
staging system based on three criteria: the depth of the bowel wall tumor intrusion, the
extent of regional lymph node invasion, and extra intestinal metastases. The depth of
tumor intrusion refers to the T stage and ranges from T1 (intrusion into the submucosa) to
T4 (intrusion into the serosa or adjacent structures). The more the tumor intrusion
increases, the higher the risk of spreading to the lymph nodes and to extra intestinal sites
(Wolpin & Mayer, 2008). The pathologic review of immediate lymph nodes shows three
N categories: N0 (no lymph nodes involvement), N1 (involve 1–3 lymph nodes), and N2
(involve more than three lymph nodes). Wolpin & Mayer (2008) emphasized the
importance of adhering to the recommended guideline of identifying 12 or more lymph
nodes in the resected specimen regional lymph nodes to prevent a poorer outcome in
patients with node-negative and node-positive disease due to under- assessment, staging
and consequently exclusion of effective adjuvant treatment.
Treatment
CRC treatment can be surgical and systemic using chemotherapy like
fluoropyrimidines for example intravenous fluorouracil, oral fluoropyrimidines, adjuvant
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therapy with fluoropyrimidines for stage III colon cancer, stage II colon cancer and
adjuvant therapy with fluoropyrimidines for stage II and stage III rectal cancer,
irinotecan, oxaliplatin, angiogenesis inhibitors, epidermal growth factor receptor
inhibitors and combine targeted therapy (Wolpin & Mayer 2008).
Fluoropyrimidines: intravenous fluorouracil is the main stay of systemic
chemotherapeutic treatment for CRC administered in combination with leucovorin and
acts via the inhibition of the enzyme thymidylate synthetase found in pyrimidine
nucleotide synthesis. Fluorouracil accounts for over 50% of tumor shrinkage accounting
for overall survival outcome, and 20% of individual with metastatic colorectal cancer will
have 50% tumor size reduction and survival rate improvement from 6months to 12
months (Wolpin & Mayer, 2008). It is pertinent to state that fluorouracil is not without
side effect and these include neutropenia and stomatitis with five weeks every day bolus
fluorouracil and leucovorin, diarrhea with bolus fluorouracil and leucovorin is given for
six to eight weeks and hematologic, gastrointestinal effect with hand and foot syndrome
and tender erythematous rash of the palm and soles when administer as continuous
infusion (Wolpin & Mayer, 2008). Oral fluoropyrimidines was initially ineffective from
poor gastrointestinal mucosa absorption until it was modified to undergo enzymatic
transformation to fluorouracil and has a similar side effect of hand and foot syndrome (an
example is Capecitabine). Tegafur is a more improved form that has better
gastrointestinal mucosa absorption.
Adjuvant therapy with Fluoropyrimidines for stage III colon cancer: The use of
adjuvant therapy in stage II colon cancer is not very clear for which it uses was not
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recommended as routine in the stage II disease. However, the stage II disease with T4
tumor penetration, bowel perforation, or clinical bowel obstruction may benefit from its
use (Wolpin & Mayer, 2008).
Irinotecan: this is a derivative of semi synthetic natural alkaloid camptothecin. It
acts through the blockage of the enzyme topoisomerase I, which catalyzes the breakage
and rejoining of DNA strands during DNA replication, SN-38 leading to the breakdown
of DNA which enhances cell death. Side effect includes diarrhea, myelosuppression,
alopecia and elevated serum bilirubin for which reason is never administered to patients
with hyperbilirubinemia (Wolpin & Mayer, 2008).
Oxaliplatin: this is a product of diaminocyclohexane platinum compound that acts
by producing DNA adducts that hinder DNA replication and cause cellular apoptosis. Its
benefit is found when in combination with fluorouracil and leucovorin otherwise it is of
limited benefit in metastatic colon cancer (Wolpin & Mayer, 2008).
Angiogenesis Inhibitors: they are blockers to the formation of new blood vessels
by blocking the vascular endothelial growth factor (VEGF) responsible for blood vessel
formation. Bevacizumab (Avastin) is an example used in combination treatment in
advanced colorectal cancer, and the side effect includes reversible hypertension,
proteinuria, bleeding episode, intestinal bowel perforation, arterial embolism, and
reversible posterior leukoencephalopathy syndrome (Wolpin & Mayer, 2008).
Epidermal Growth Factor Receptor Inhibitors: they are agents that block
epidermal growth factor receptor (EGFR) and prevent signaling pathway hindering
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cellular growth, proliferation, and enhancing program cell death (Wolpin & Mayer,
2008).
Combined Targeted Therapy: the use of combined therapy in the treatment of
CRC is ongoing to determine the efficacy of combining monoclonal antibodies with
VEGR and EGFR in individuals with metastatic CRC (Wolpin & Mayer, 2008).
Screening: the screening for CRC has increased in the United States, but not
enough people are getting screened for CRC (CDC, 2017). The screening process for
CRC has been successful in detection due to the early detection of the pre-cancerous
colorectal polyps or early-stage cancer prior to the symptoms manifestation, and before
the disease grows, metastasized which allow easy to manage treatment that is not
expensive, and has better chance of being successful (Marley & Nan, 2016). In 2014,
65.7% of U.S adults were current with CRC screening; 7% was screened but not current,
and 27.3% were never screened (CDC, 2017).
It is recommended by the Centers for Disease Control and Prevention (CDC) and
the U.S. Preventive Services Task Force that all men and women between the ages of 50
and 75 should be screened for colorectal cancer using fecal occult blood testing (FOBT),
sigmoidoscopy, or colonoscopy (Marley & Nan, 2016). Nine out of every ten whose CRC
is detected early and promptly treated tend to have five years survival time (CDC, 2017).
FOBT is an annual test that uses guaiac or antibodies to detect blood is a patient’s
stool sample to confirm colorectal cancer. The stool sample is collected in a specimen
sample bottle test kit that returns for laboratory analysis (Marley & Nan, 2016). FOBT is
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an inexpensive, easy to administer simple test which enables countries to adopt it as a
better national screening test.
Sigmoidoscopy is an endoscopic procedure recommended every five years for
direct visualization of the lower colon and rectum using a thin, flexible tube inserted into
the rectum to visualize any pre-cancerous polyps or any existing cancer. This test is like
colonoscopy except that a longer thin flexible tube is required since the whole length of
the colon will be a scope. This procedure also includes polypectomy which is the removal
of polyps during the scoping process and is recommended every 10years (Marley & Nan,
2016). Other screening methods include double-contrast barium enema, and the stool
DNA test.
It has been shown that screening for a 50-year-old asymptomatic person should
start due to the finding of exponential increase risk of colorectal pathogenesis and
carcinogenesis (Marley &Nan, 2016). However, despite these recommendations and the
successful outcome obtained from screening, certain issues kept the screening rate low in
the United States (Marley & Nan, 2016). One of these issues includes the pattern noticed
among African Americans which is a combination of enhancing risk and low screening
and early presentation with CRC among African American population compared to
Caucasian Americans (Marley & Nan, 2016). African American have a higher chance of
dying from CRC. According to Marley and Nan, (2016), only 56% of African Americans
above the age of 50 are compliant with the recommended screening guidelines, compared
to 62% of Caucasians. This finding encouraged the advocacy for early screening age for
African American population (Dagusta, Youlden & Baade, 2012).
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Prevention and Control
There are many ways the prevention and control of colorectal cancer can be
achieved. This includes dietary intake like the regular consumption of fish, fiber, vitamin
D, and calcium, as well as aspirin intake and regular exercise, (Marley & Nan 2016). The
intake of anti-inflammatory drugs with dietary change prevent the growth of new polyps
and curb the growth of existing polyps (Marley & Nan, 2016).
Community /family interventions can be helpful in the prevention of colorectal
cancer using family-based support for the person with colorectal cancer such as the use of
encouraging words as a motivation measures during screening, exercising, and adopting a
healthy diet, can be an effective learning tool to help with carcinogenesis prevention.
Surgical Treatment
Rectal cancer is surgically treated with total mesorectal excision with a high tie of
the inferior mesentery artery to remove some lymph nodes with the specimen. It was also
recommended that colonic surgery should follow a similar pattern mesocolic excision
with dissection of the lymph nodes, but there is limited evidence-based information of the
benefit to survival rate (Augestad, Merok & Ignatovic, 2017).
Surgical treatment is usually a radical intervention and include right or left
hemicolectomy, segmental colectomy on the transverse or sigmoid colon, subtotal or total
colectomy, with digestive continuity reestablished by ileocolic, colo-colic, colorectal or
even ileorectal anastomosis or palliative (colostomy or colonic bypass in advanced nonresectable stages). Mastalier et al. (2012), assert that the tumors that have perforated
nearby organs may lead to a block resection associated with distal splenopancreatectomy,
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gastrectomy, etc. The tumor removal could end with the creation of colostomy for 3-6
months before reestablishing the digestive continuity by closing the colostomy.
Postoperative surveillance: It is reported that 40% of all CRC patients surgically
cured will have a recurrence within five years after surgery. 80% of the recurrence will
occur within 2years of the surgery, and this raises the issue of enrolling survivors in the
post-operative surveillance program to ensure early detection of recurrence. According to
Augestad, Merok & Ignatovic, (2017) the purpose of surveillance programs is to enhance
early detection of recurrence and provide metastatic salvage surgery, ensure continuous
monitoring of the effects of programs, and the social consequences of cancer
survivorship. However, the success of this surveillance program although said to be 10%
increase in survival, has been questionable by the findings in other studies (Augestad,
Merok & Ignatovic, 2017).
Complications of CRC
These include intestinal occlusion by the tumor, localized or generalized
peritonitis when the tumor perforates the colon, diastatic cecum perforation, the creation
of fistula in a nearby organ like duodenum, small intestine, stomach, and finally death
(Mastalier et al., 2012).
Second Primary Cancers
Individuals with CRC have been reported to be at risk of developing other
cancers, and these second cancers may adversely affect the prognosis and survival time
(Lee et al., 2015). Second cancer which develops after diagnosis with CRC could be
either secondary or a second primary cancer. Secondary cancer is metastases of the same
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histological cell type with primary cancer while the second primary cancer is of different
histological cell type arising after primary cancer. Youlden and Baade, (2011)
investigated the relative risk of cancer survivor developing second cancer in the
Australian population and discovered that the relative risk of developing an SPC is higher
compared to the population. Lee et al. (2015) demonstrated that the incidence of SPCs is
higher in patients with CRC than in the general population (IR = 1.13).
Secondary cancer occurs when the primary or initial cancer cells metastasize to
another part of the body resulting in the formation of a new tumor of the same
histological type with original cancer. CRC cells can metastasize from the primary cancer
site through the lymphatic cells or the bloodstream to the liver, lung, bones, and other
parts of the body (National Cancer Institute, 2017). Symptoms depend on the specific
part of the body with the metastasis.
Lee et al. (2015) determined an increased risk of developing a second primary
malignancy in a Taiwanese CRC population. Second cancers of the CRC were excluded
to rule out the secondary cancer of the same histological origin. Results indicated excess
risk for cancer of bladder, stomach, kidney, lung, prostate, ovarian, breast, thyroid and
endometrium (Evans, et al. 2002, Ahmed et al.,2006, Youlden & Baade, 2011),
Lee et al. (2015) investigated the incidence of SPC among Taiwanese population
and identified independent risk factor of SPC to include Age, men, COPD, cirrhosis, and
dyslipidemia. The present percentage of SPC in the total number of cancers ranges from
0.73% to 11.70%, and the trend is increasing (Sun et al., 2015). Lee et al used
Multivariate analysis to show that age ≥ 70 years (hazard ratio [HR] = 1.40, 95%
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CI = 1.32–1.50; P < 0.001), men (HR = 1.44, 95% CI = 1.35–1.53; P < 0.001), liver cirrhosis
(HR = 2.05, 95% CI = 1.77–2.39; P < 0.001), COPD (HR = 1.21, 95% CI = 1.12–1.30;
P < 0.001), and dyslipidemia (HR = 1.16, 95% CI = 1.07–1.26; P = 0.001) remained
significant independent predictors of cancer development (Lee et al., 2015). OritzMendoza et al. (2016) in a study done in Mexico showed that obese females are more
significantly affected than males raising the question of the impact/roll of the obesity
induced metabolic syndrome in causing SPC among female CRC survivors. Dasgupta,
Youlden & Baade showed that CRC survivors in their cohort had a significantly higher
risk of developing subsequent colorectal (SIR = 1.47, 95% CI 1.30-1.66) or noncolorectal cancers (SIR = 1.24, 95% CI 1.18-1.31) and the risks were significantly higher
for both male and female when compared to population of the same age in Queensland
population.
Examples of SPC (Lung, Bladder, Kidney, Gastric, and Endometria Cancers)
Lung cancer: Lung cancer is the leading cause of cancer death and the second
most common cancer among both men and women in the United States (CDC, 2017).
Cancer starts in the lung and can spread to lymph node or other organs like the brain and
other parts of the body as metastases. Lung cancer has two main types, the small cell and
non-small cell lung cancer which is more common (CDC, 2017).
Smoking cigarette is the most important risk factor that is linked to 80-90% of
lung cancer and can cause cancer in any part of the body (mouth, throat, esophagus,
stomach, colon, rectum, liver, pancreas, larynx, trachea, bronchus, kidney, and renal
pelvis, bladder and cervix and acute myeloid leukemia). Smoking is a cause of CRC

44
(American Cancer Society, 2017). The cigarette has 7000 toxic chemicals that are mainly
poisonous (CDC, 2017). Smokers are 15 to 30 times likely develop lung cancer or be
killed by lung cancer than individuals that are non-smokers.
Second-hand smoke from other people’s cigarette, pipe, or cigars is also a risk
factor for lung cancer. Radon gas that cannot be seen, smell or taste naturally trapped in
houses and dirt can cause lung cancer. Other work-related exposures like asbestos,
arsenic, diesel exhaust, silica, and chromium are associated with lung cancer (CDC,
2017). Personal of family history of lung cancer could be a risk factor. Having a relative
brother, sister, parent, or children that have had lung cancer is a risk factor. Radiation to
the chest in a cancer survivor can predispose the patient to develop. The role of diet is
still ongoing but drinking arsenic in water clear as a risk factor for lung cancer.
Jian et al (2013) conducted a study in Taiwan and found an association between
lung adenocarcinoma and CRC in both sexes in cross-township but not in the cross
country. The author found a significant correlation between colorectal cancer and lung
adenocarcinoma in men (r=0.526, P=0.021), but not in women.
Endometrial Cancer: Endometrial cancer is the cancer of the endometrium that
originates from cells lining the inner part of the uterus (the endometrium). Endometrial
cancer represents the most common cancer found in the female reproductive system and
accounts for 6% of all female cancers in the United States [National Cancer Institute
(NCI), 2014]. Endometrial cancer can be squamous cell carcinoma, adenocarcinoma, and
undifferentiated carcinoma, based on the histologic cell type seen under the microscope
(American Cancer Society, 2015). There are risk factors associated with increased risk of
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endometrial cancer such as genetics, obesity, early menarche, postmenopausal estrogen
therapy, tamoxifen use, and late menopause (NCI, 2014). The incidence rate of
Endometrial cancer among the African American women is higher compared to White
women, and the mortality rate is twice other ethnic/racial population (NCI, 2014). Oliver
et al. (2001) shows that African American women are likely to present late with advanced
stage cancer and more likely to have non-endometrioid, high-grade tumors at the time of
diagnosis compared to Caucasian women who have similar demographics. Menopausal
women account for most individuals diagnosed with endometrial cancer, with an average
age of diagnosis of 60. Oncolink, (2015) reveal that Endometrial cancer is less common
in women less than 40 years of age (5-10%). Patients with an initial diagnosis of CRC
may have an increased risk of developing a type of endometrial cancer later (Singh,
Singh, Miller, Strum & Coyle, 2012). CRC is associated with endometrial cancer, and
10% of endometrial cancer could be due to hereditary none- polyposis CRC while the
majority is not genetic. Singh et al.(2012) conducted a CRC screening study involving
267 women with endometrial cancer, 39% were less than 60years at diagnosis, median
age was 66, and 25 (9.4) of endometrial cancer patients has family history of CRC, 125
women had CRC screening with 12 (9.6%) being screened for CRC within 1 year of
diagnosis and 33 (26.4%) screened for CRC before endometrial cancer diagnosis. 142
women (53.2%) did not have CRC screening reported, and of those women screened, ten
had adenomatous polyps with one having polyps that are greater than 1cm, four had
tubulovillous histology, and three had CRC. This reinforces the association between
CRC and endometrial cancer.
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Gastric cancer: Gastric cancer is a slowly growing tumor that arises from the
inner lining of the stomach and may not be detected. Cancer can start in the different part
of the stomach like gastro esophageal junction, cardia and can metastasize in different
ways. These cancers are capable of growing and invading surrounding organs and
spreading to distance organ through the invasion of lymph vessels and surrounding lymph
nodes and blood stream in advance case spreading to the liver, lungs, and bones
(American Cancer Society, 2017). Symptoms include weight loss due partly to poor
appetite, abdominal pain, nausea, vomiting with or without blood, vague abdominal
discomfort, heart burn, feeling of fullness on eating small meal, swelling or fluid
accumulation, anemia (American Cancer Society, 2017). Gastric cancer has different
histological cell types like adenocarcinoma, lymphoma, gastrointestinal stromal tumor
(GIST), Carcinoid tumor and others like squamous cell carcinoma, small cell carcinoma,
and leiomyosarcoma. Early detection is possible using upper endoscopy to detect cancer,
and a biopsy can be obtained for histological cell type analysis. There is a place for
imaging test using x-ray, magnetic fields, sound waves, or radioactive substances to
create pictures of the body. This will help detect the lesion and its location, assess its
spread and what treatment option will be effective. Surgical intervention is the main stay
of treatment supported by adjunct treatment like chemotherapy, targeted therapy, and
radiation therapy. Jian et al. (2013) in a study in Taiwan reported that significant crosscountry correlations in colorectal cancer (r=0.918, P<0.001), gastric cancer (r=0.985,
P<0.001) and lung adenocarcinoma (r=0.685, P=0.001) were observed between men and
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women. There were links of lung adenocarcinoma and gastric cancer (r=0.122, P=0.024)
and colorectal cancer (r=0.128, P=0.018) in women.
Bladder cancer: Each year in the United States, about 55,000 men and 17,000
women get bladder cancer (CDC, 2017). Men are three times likely to have bladder
cancer than women, with the white Caucasian having the highest rate of getting bladder
cancer (36.4 per 100,000 men), followed by black men (19.0), Hispanic men (18.6),
American Indian/Alaska Native men (14.8), and Asian/Pacific Islander men (14.0) (CDC,
2017). Among the women, white women had the highest rates of getting bladder cancer
(9.0 per 100,000 women), followed by black women (6.4), Hispanic women (4.8),
Asian/Pacific Islander women (3.7), and American Indian/Alaska Native women (3.4)
(CDC, 2017). According to 2014 statistic, 15,775 (11,291 men and 4,484 women) died
from bladder cancer (CDC, 2017).
The primary risk factor associated with bladder cancer development is smoking
and other risk factors include chronic urinary tract infection, gene mutation, family
history of bladder cancer, exposure to chemicals like dye, metal, and petroleum at work,
use of chemotherapy drugs, ingestion of good water contaminated by arsenic and use of
chines herbal preparation known as Aristolochia fangchi (CDC, 2017). The risk for
bladder cancer can be reduced by not smoking.
The common symptom is blood in the urine, frequent urination and pain while
urinating. There could be back pain and pelvic pain. In a study conducted by
Calderwood, Huo, & Rubin (2008) the risk for developing urologic cancer increased after
a diagnosis of CRC (SIR, 1.24; 95% CI, 1.20-1.28) but the highest risk is for subsequent
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renal pelvis and ureteral cancers in patients with a CRC diagnosis before the ages of 50 to
60 years or with multiple primary CRCs.
Kidney cancer: The most common kidney cancer is the renal cell carcinoma
account responsible for 90% of all kidney cancer cases, 2.4% of all adult cancer cases
and mortality of 140,000 death annually (Emory Winship Cancer Institute, 2016). Renal
cell carcinoma (RCC) is common in males than females and varies in geographic
variation with a higher rate in Europe and North America than Asia and South America
(Emory Winship Cancer Institute, 2016). The direct cause of kidney cancer is unknown,
but there are risk factors like smoking, obesity, genetic predisposition, and hypertension.
Men who smoke have 50% more risk of developing RCC than non-smokers. Obesity
increases the risk of developing RCC by 24% in men and 34% for women (Emory
Winship Cancer Institute, 2016).
RCC is detected on physical examination and using CT scans, Ultrasound,
PETscan and blood test. Thompson et al. (2006) in their study 2,188 (80.4%) participants
had a clear cell, 378 (13.9%) had papillary, and 128 (4.7%) had chromophobe renal cell
carcinoma. Patients with papillary renal cell carcinoma were significantly more likely to
have colon cancer (p = 0.041). This shows there is a possible association between colon
cancer and RCC.
Metabolic Syndrome (MetS)
Also, known many names such as syndrome X, metabolic disease, insulin
resistance syndrome or dysmetabolic syndrome. MetS is a combination of conditions that
when taken together can increase the risk of development of heart disease, stroke,
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diabetes, stroke, and other chronic health problems like cancer. Moore, Chaudhary &
Akinyemiju, (2017) state that the diagnosis of MetS is made when any three of the
following five components are present:
•

Abdominal obesity (apple-shaped).

•

Hypertension

•

Dyslipidemia- Low levels of HDL cholesterol in the blood

•

Dyslipidemia- High levels of triglycerides in the blood

•

Diabetes mellitus type 2.

Metabolic syndrome is not a diagnosis but serious health condition (America
Heart Association, 2015). MetS affect 30% of the U.S population. MetS affect 4 out of 10
Americans as they get to 60 and 70 years. This syndrome is becoming more common in
the United States. Over 30 percent of adult Americans are estimated to have MetS
(Moore, Chaudhary & Akinyemiju, 2017). The prevalence of MetS has gradually
increased since 2007 from 25.3% to 34.2% in 2012 (Moore, Chaudhary & Akinyemiju,
2017). The prevalence of MetS was higher in women compared to men between 2003 to
2012 and considering race/ethnicity, the highest prevalence was seen in Hispanics,
followed by non-Hispanic whites and blacks (Jong, 2015). MetS increasing prevalence
has been reported among Chinese elderly (Liu et al., 2013) and is fast becoming a serious
global challenge.
According to Weil (2017), there is no physical symptom for MetS but the
symptoms of its components. Thus, there is obesity, hypertension, the clinical symptom
of diabetes resistance, etc. There is high level of insulin which will cause chronic
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inflammation, damage thickening of the blood and arterial wall damage (Weil 2017).
Some studies have found sex differences in risk predictors of MetS, which could suggest
possible role of sex hormone levels and androgen/estrogen balance in determining MetS
(Hadaegh et al., 2017; Kim HA, Lee SY, Kwon HS, Lee SH, Jung MH et al. 2013). MetS
is a chronic problem which develops if not corrected.
The National Cholesterol Education Program’s Adult Treatment Panel III report
(ATP III) was used by WHO and provided the criteria for diagnosis of MetS based on the
following criteria:
•

A waist circumference of more than 40 inches for men and over 35 inches for

women).
•

Fasting glucose of 100 mg/dL or more or on medication high blood glucose

•

Fasting blood triglycerides of more than 150 mg/dL or on medication for high

triglycerides treatment.
•

Low HDL cholesterol levels or on medication for low HDL cholesterol

treatment: 40 mg/dL for men and < 50 mg/dL in women.
•

High blood pressure >140/90 mmHg or taking medication for hypertension.

Abdominal obesity is the increased waist circumference and the form of obesity
that is most frequently associated with MetS (American Heart Association, 2004).
Dyslipidemia is characterized by raised triglycerides and low concentrations of
HDL cholesterol obtained through Lipoprotein analysis (AHA, 2004). Abnormal
lipoprotein analysis obtained are atherogenic and include low HDL level, increased
remnant lipoproteins, elevated apolipoprotein B, and small LDL level (AHA, 2004).
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Elevated blood pressure is commonly found in insulin-resistant individuals and it
is strongly associated with obesity due especially to its contribution to the arterial
thickness in older individuals (AHA, 2004).
Insulin resistance is common among many people with metabolic syndrome, and
it strongly associates with other metabolic risk factors. Chronic insulin resistance
enhances the development of glucose intolerance, another emerging risk factor.
Another important contribution to MetS is the proinflammatory state, clinically
described by the elevations of an acute-phase protein like C-reactive protein (CRP) which
is characteristically found in individuals with metabolic syndrome (AHA, 2004; Chen,
Yen, Huang, Lee, Hsia & Lin 2012). Obesity is a cause of elevated CRP level among
other causes due to the release of inflammatory cytokines from the numerous obese
individual’s adipose tissues (AHA, 2004).
MetS are also associated with a prothrombotic state, characterized by increased
plasma plasminogen activator inhibitor (PAI)-1 and fibrinogen. The levels of Fibrinogen
and CRP rises in response to a high-cytokine state to establish the possible metabolic
connection between prothrombotic and proinflammatory states (AHA, 2004).
Measuring levels of CRP is useful as a marker in some disease to determine
progress or effectiveness or treatment and an increased basal level of CRP predisposes to
increase the risk of diabetes, hypertension, and cardiovascular disease (Jain, Gautam &
Naseem, 2011). CRP (CRP rs1205 AA genotype) is associated with the increased risk of
development of colon and rectal cancer (Slatter et al., 2011).
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MetS component causes cells to lose sensitivity to insulin accounting for the
insulin resistance and causing a buildup of glucose in the blood. The pancreas repeatedly
compensates by producing more insulin causing the characteristic effect that is
responsible for MetS (Weil, 2017). The high insulin level triggers a stress response that
causes the release of cortisol, the body’s long-acting stress hormone. This, in turn, trigger
an inflammatory reaction that damage healthy tissue if left unchecked (Weil, 2017).
Foods enhancing obesity and insulin resistance may enhance MetS. These
include sodas, ice cream, jams, jellies, salad dressing ketch up, etc. (Weil, 2017). Sleep
apnea also contributes to the development of MetS (Weil, 2017).
The cause of MetS is unknown, but certain factors have been implicated in the
etiology of MetS including factors such as dietary intake and lifestyle.
There are three known sources of origin of MetS: obesity and disorders of
adipose tissue; insulin resistance; and groups of independent factors like molecules of
hepatic, vascular, and immunological in origin which arbitrates for some component of
MetS. There are other contributing factors like age, proinflammatory condition and
hormonal changes (AHA, 2004).
The increasing incidence of obesity is considered to be responsible for the
increasing prevalence of MetS (AHA, 2004). Obesity is known to enhance high serum
cholesterol, hypertension, hyperglycemia and low HDL and is consistent with metabolic
risk factor (AHA, 2004). In obesity, there are lots of adipose tissue that produce different
products like adiponectin, cytokines, non-esterified fatty acids (NEFA), and PAI-1 which
further aggravate the risk factors. Insulin resistance is enhanced by the high level of
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NEFA which fills the liver and the muscle with lipid. Obesity is usually accompanied by
high CRP levels which encourage increase cytokine and proinflammatory state (AHA,
2004). A high PAI-1 promotes the prothrombotic state, whereas low adiponectin levels in
association with obesity further worsening metabolic risk factors (AHA, 2004).
Insulin resistance increases as the body fat level increases. Obesity (BMI ≥30
kg/m2) predisposes to postprandial hyperinsulinemia with a comparative low insulin
sensitivity, although this sensitivity varies among the obese population (AHA, 2004).
Role of Independent Factors in Metabolic Syndrome
There are independent factors that mediate each risk factors of MetS such as
genetic and acquired factors which introduce some variability in the expression of these
risk factors (Roberts, Hevener & Barnard, 2013). Blood pressure and lipoprotein
metabolism are regulated by genetic differences while glucose levels depend on the
insulin-secretory ability and insulin sensitivity (Hardy, Czech & Corvera, 2012). This
variation constitutes an important factor in the etiology and pathogenesis of metabolic
syndrome.
Another contributing factor to the pathogenesis of MetS is the increasing age
which provides answers to why MetS prevalence increases with advancing age (AHA,
2004). A proinflammatory state has been directly associated with the etiology of insulin
resistance, and atherogenesis. Endocrine factors have also been linked to abnormalities in
distribution of the body-fat and its indirectly association to metabolic syndrome shows
the composite nature of MetS pathogenesis (AHA, 2004).
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The aim of the treatment is to eliminate the risk factors: stop smoking, treat
diabetes, control the blood pressure, treat blood lipid abnormality, start exercise and
ensure healthy dietary intake (America Heart Association, 2015). Elevated blood pressure
should be treated using lifestyle modification therapy. The use of antihypertensive drugs
in the guidelines for hypertension is recommended as there is no specific type of
antihypertensive that is specific for treatment of individuals with MetS (Moran et al.,
2015; AHA, 2004).
Dyslipidemia should be treated using LDL-lowering drugs like statins to reduce
apolipoprotein B containing lipoproteins which is beneficial in MetS individual due to
reduced risk of cardiovascular disease (CVD) event (AHA, 2004). Treatment with
fibrates combined with statin gives a better outcome in treating abnormal lipoprotein
level (Agouridis, Rizos, Elisaf & Filippatos 2013; AHA, 2004).
There is no drug treatment that targets PAI-1 and fibrinogen. The use of
antiplatelet therapy like low-dose aspirin has been described for primary prevention of
CVD in MetS (Stegeman, Bossuyt, Yu, Boyd & Puhan 2015; AHA, 2004).
Hyperglycemia predisposes individuals with MetS to high risk for CVD.
Hypoglycemic agents should be used to reduce the A1c to levels below stipulated normal
value in addition to using lifestyle modification (AHA, 2004, American Diabetes
Association, 2013).
The use of lipid-lowering drugs like statin or fibrates reduces the proinflammatory
state and reduce CRP levels (AHA, 2004, Chen, et al., 2012).
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Summary and Conclusion
The incidence of CRC is increasing while the mortality is reducing due to the
screening test and better treatment approach which now is predisposing them to a higher
risk of developing SPC (Guan et al., 2015). SPC among CRC survivors is a new cancer
challenge that is threatening CRC survivors especially with the first five years after
primary cancer (Yang et al 2017). A lot is much yet to be learned about the pathogenesis
of the origin of SPC and the factors that trigger the malignancies. In this chapter the
current state of knowledge for the variables that were used in this study was reviewed,
including the component of MetS (abdominal obesity, hypertension, hyperglycemia,
hyperglyceridemia, dyslipidemia), age, gender, and ethnicity as risk factors for second
primary cancers among CRC survivor’s population.
MetS have been implicated in association with many diseases which include CRC
and its association with SPC. The site of the SPC has been influenced by the anatomic
site of primary cancer as shown in figure1 below (Raj et al., 2011). The common highrisk sites for SPC are those with origin from the embryonic endoderm (Yang et al., 2017).
A right-sided colon cancer (ascending colon in figure1) was linked with SPC of the
stomach, small intestine, pancreas, ureter, pelvis, renal, breast, and thyroid. The left-sided
primary colon cancer (descending colon in figure1) was linked with secondary CRC,
whereas rectal cancer was linked with SPC of the lungs, vagina, and urinary bladder
(Yang et al., 2017).
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The tumor site was important as the risk for developing an SPC was higher only
among those whose initial tumor was in the descending colon (SIR=1.6; 95% CI: 1.3 to
2.0) compared to the proximal colon (SIR=1.4; 95% CI: 1.3 to 1.6) (Raj, et al., 2011).
The large intestine is the site where inflammation takes place and influences
carcinogenesis through a complex mechanism (Slattery et al., 2011). One of the
mechanisms highlighted is via the activity of the CRP an inflammation biomarker
triggered by an increase in plasma cytokine level IL6 which increases the level of CRP
associated with high risk of CRC whose strong determinant is BMI (Slattery et al., 2011).
Obesity has numerous adipose tissue which predisposes to having both high CRP
and promote high hyperglycemia, hypertension, low HDL and serum cholesterol, which
is compatible with metabolic risk factor (AHA, 2004; Kaur, 2014). Obesity in
conjunction with MetS has been implicated as index of worse survival in early stage CRC
(Cespedes-Feliciano et al., 2016).
Gender plays a role in SPC among CRC survivors as the incidence of SPC among
CRC survivor was higher in females (SIR=1.5; 95% CI: 1.3 to 1.6). In Europe, both age
and gender has been found to influence the prevalence and prognostic significance of
MetS (Vishram et al., 2015).
The enormous risk of developing SPC among CRC survivors associated with
obesity, insulin resistance or independent factors induced MetS. The poorer prognosis for
individuals with SPC, particularly those with endometrial, kidney, lung, stomach, and
bladder cancer, necessitate a better understanding of the risk factors associated and
adoption of surveillance in the CRC survivor population. The results obtained from this
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study will aid clinicians in determining appropriate screening and importance of timely
treatment and interventions to reduce mortality and improve health outcomes.
Chapter 3 will focus on the choice of the appropriate research design for the study
and the rationale for the design, the power analysis engaged and sample size estimate, the
target population, the sampling and sampling methods, instrumentation used and
materials, secondary data collection and process of analysis using the dependent variable,
independent variables, and the research questions. The chapter ends with quality
assurance and how human subjects are protected.
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Chapter 3: Research Method
Introduction
Colorectal cancer survivors are known to have other health issues, but the major
concern is to have to deal with another cancer (American Cancer Society, 2017; Raj et
al., 2009). Science has achieved some progress in the management of CRC by the
introduction of early screening intervention, which has enhanced survival rate. However,
the euphoria of this success due to declining mortality but increasing incidence hardly
ended before researchers started detecting the emergence of lethal and life-threatening
cancer types among these survivors (Guan et al., 2015). These emerging cancers are the
SPC associated with CRC from the bladder, kidney, stomach, lungs, and endometrium.
Individuals with previous colorectal cancer are subject to the same risk of cancers types
that other people get (American Cancer Society, 2017). The incidence of the SPC among
CRC is on the increase (Guan et al., 2015; Lee et al., 2015). The probability of
developing SPC was 33% higher (95% CI; 1.12–1.56) for CRC that received surgical
treatment and 45% higher (95% CI; 1.29–1.64) after proximal colon cancers relative to
rectal cancer (Dasgupta et al., 2012).
MetS has been associated with etiology CRC in the literature due to its complex
components (high blood pressure, abdominal obesity, diabetes mellitus,
hypertriglyceridemia, hypercholesterolemia), which are health risk factors that act either
independently or complimentary in action and effect to cause acute stroke,
cerebrovascular accidents, heart attack, and chronic diseases like CRC that can lead to
morbidity and mortality (Cespedes-Feliciano et al., 2016). One recent study has revealed
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that the more MetS components that are present, the higher the risk of death, even in the
absence of obesity (Cespedes-Feliciano, et al., 2016). Individual MetS components show
adverse and protective relationships that depend on how they are defined and measured
and affect their influence on survival and outcomes due to paradoxical associations with
each component, which has led to conflicting survival results (Cespedes-Feliciano et al.,
2016). However, there is an existing relationship between obesity associated MetS and
CRC as both obesity and MetS have been implicated with worse survival prognosis
among early stage (I-III) CRC Patients (Cespedes-Feliciano et al., 2016). MetS is
associated with an increased incidence and mortality as well as the risk of colorectal
cancer in both sexes, and the risk expressed by the full MetS is not higher to the sum of
the MetS components (Esposito et al., 2013). Moreover, obesity associated MetS in a
Mexican study has been shown to be associated with SPC, especially in obese Mexican
women (Oritz-Mendoza et al., 2016).
Guan et al. (2015) reported an increased incidence of SPC among CRC survivors
aged 20 to 40 years, American Indian/Alaska Native due intensive treatments for initial
CRC, normal aging, and continuous exposure to carcinogens.
The incidence of SPCRC was found to be higher in females (SIR = 1.5; 95% CI:
1.3 to 1.6) and Hispanics (SIR = 2.0; 95% CI: 1.7 to 2.4) with primary colon cancer to
confirm that the risk of SPC among CRC survivors is higher with gender (female) and
ethnicity (Hispanic) than the general population (Raj et al., 2009). A similar study done
in Mexico found an association between obese female Hispanics and the development of
SPC among CRC survivors (Ortiz-Mendoza & De la Fuente-Vera, 2014). The
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identification of incidence characteristics of SPCs is essential for continuous cancer
surveillance among CRC survivors (Guan et al., 2015).
The purpose of this study was to fill the gap in the literature by demonstrating the
existence of an association between MetS and SPC among colorectal cancer
survivors/deceased. I used a quantitative research method and selected participants with
SPC after CRC into a cohort group and a control group with CRC treatment but no
second primary cancer as another cohort. I investigated the association between MetS
with both groups and compared the results.
In this chapter, I describe the research design as well as the rationale with an indepth description of the study methodology, including population, sampling, and
sampling procedures of the secondary data. I also include the operationalization of
constructs, instrumentation, data analysis plan, as well as the threats to internal and
external validity and ethical procedures.
Research Design and Rationale
The purpose of this study was to fill the gap in the literature by demonstrating any
existing association between MetS and/or its components and SPC among CRC
survivors/deceased. I studied three main areas that included MetS and SPC in CRC
survivors/deceased. The independent variables were hypertension, abdominal obesity,
diabetes, dyslipidemia, and hypertriglyceridemia, and the dependent variable was SPC
among CRC survivors/deceased.
Research Questions
RQ1: Is there an association between hypertension and SPCs in CRC patients?
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Hypotheses
H01: There is no association between hypertension and SPCs in CRC patients.
Ha1: There is an association between hypertension and SPCs in CRC patients.
Research Question 2
RQ2: Is there an association between abdominal obesity and SPCs in CRC patients?
Hypotheses
H02: There is no association between abdominal obesity and SPCs in CRC patients.
Ha2: There is an association between abdominal obesity and SPCs in CRC patients.
Research Question 3
RQ3: Is there an association between dyslipidemia and SPCs in CRC patients?
Hypotheses
H03: There is no association between dyslipidemia and SPCs in CRC patients.
Ha3: There is an association between dyslipidemia and SPCs in CRC patients.
Research Question 4
RQ4: Is there an association between diabetes and SPCs in CRC patients?
Hypotheses
H04: There is no association between diabetes and SPCs in CRC patients.
Ha4: There is an association between diabetes and SPCs in CRC patients.
Research Question 5
RQ5: Is there an association between hypertriglyceridemia and SPCs in CRC patients?
Hypotheses
H05: There is no association between hypertriglyceridemia and SPCs in CRC patients.
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Ha5: There is an association between hypertriglyceridemia and SPCs in CRC patients.
Research 6
RQ6: Is there an association between age, gender, and ethnicity with SPCs in CRC
patients?
Hypotheses
H06: There is no association between age, gender, and ethnicity and SPCs in CRC
patients.
Ha6: There is an association between age, gender, and ethnicity and SPCs in CRC
patients.
RQ7: Is there an association between MetS and SPCs in CRC patients?
Hypotheses
H07: There is no association between MetS and SPCs in CRC patients.
Ha7: There is an association between MetS and SPCs in CRC patients.
The aim of the study was to assess the variables at a particular time, over 6
months after treatment of CRC, and to compare them with CRC survivors with SPC.
The first cohort consisted of men and women with a diagnosis and treatment of colorectal
cancer without SPC. The second cohort included both men and women with a diagnosis
of SPC among CRC survivor/deceased. The variables under study are described in Table
1.
I did not expect any time or resource constraints for this study design choice. However,
there was a delay in getting the appropriate dataset for the study. The study was a
quantitative retrospective cohort study using secondary data collected over 3 years by the
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SEER- Medicare (2011-2013). These data were accessible at a cost to use by researchers
after signing a collaboration agreement form
I selected a quantitative cohort study design for this study due to its use in similar
studies (see Houser, 2012). The quantitative cohort study design is good at determining
relationships between a risk and an outcome, with causality inferred based on varying
criteria. The relationship between MetS component risk factors and SPC among CRC
disease cannot be tested using an experimental design due to the unethical reason of
exposing individuals to risk factors they would otherwise not experience.
The choice of a quantitative study design did not give the opportunity to control
some extraneous, modifiable variables; this served as a limitation to this study. Examples
of extraneous variables that were not controlled for are genetically induced CRC
conditions like familial adenomatous polyposis, hereditary nonpolyposis colorectal
cancer, Lynch syndrome, Turcot syndrome, Peutz-Jeghers syndrome, smoking, and
alcohol-related CRC.
Table 1
Research Questions (RQ), Independent Variables and Cohort
Research question
Independent variables
RQ1
deceased

Hypertension

Cohort

Group of CRC survivors/
Men and women without

SPC.
RQ2
RQ3
RQ4
deceased

Abdominal obesity
Dyslipidemia
Diabetes

RQ5

Hypertriglyceridemia

Group of CRC survivors/
Men and women with SPC.
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RQ6
Age, gender, and ethnicity
RQ7
MetS
Note. In each case, the dependent variable is the diagnosis of second primary cancer
(SPC).
Methodology
Study Population
In this study, I used secondary data from the (SEER-Medicare. The SEERMedicare contains data on the general population as well as clinic-based data. The SEERMedicare database is used for doing population-based case-control studies to show the
causes of cancer among the U.S. elderly (Engels et al., 2011). This database is the
product of the electronic merger of SEER and Medicare data
(http://healthservices.cancer.gov/seermedicare/). The linkage incorporates name, Social
Security number, sex, and date of birth to create a match that is 94% successful to SEER
cancer cases for those over the age of 65 with Medicare coverage, while 3% of the
elderly are without Medicare coverage, and another 3% lack sufficient information for
the merger (Engels et al., 2011). The SEER-Medicare linkage is upgraded every 2 years,
and identifiers are removed from the resulting merged files (Engels et al., 2011). The
study population was obtained from the dataset of CRC cases reported from 2011 to 2013
of both genders, totaling 58,171 cases (National Institute of Health, 2017).
The SEER-Medicare collects health data from persons across a wide spectrum of
CRC risk. These data are from colorectal cancer persons through population-based
cancer registries, clinical settings, and community covering 26% of the U.S population.
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The study population from the dataset included male and female patients diagnosed with
colorectal cancer for over a five-year period from 2011-2013 in the dataset. The dataset
provides information on colorectal cancer, age, gender, ethnicity, and any diagnosis of
second primary cancer of colorectal cancer like lung, stomach, endometrial, kidney and
bladder after an initial diagnosis of colorectal cancer.
Sampling Procedures
The sampling procedure include random selection of participants from 58,171
cases of CRC reported by SEER-Medicare from 2011-2013 period into two cohorts.
Cases were compared with a subset (a sample) of the “risk set”. The cohort members who
initially are at risk could be included in the subset when such member becomes a case
especially in cases of SPC. The choice of this method allowed cases that occur later
during the follow-up to be eligible for inclusion in the controls for earlier cases (Szklo &
Nieto, 2014). For this study, all cases were drawn from the same cohort, and then the
correct number of subjects with second primary cancers were selected and then matched
with those without second primary cancers.
The study sample was made of adults male and female participants diagnosed
with colorectal cancer based on the inclusion criteria which include presence of CRC
subjects must have been diagnosed with a colorectal or colorectal cancer-related second
primary cancer, lung, endometrium, kidney, bladder, and stomach during the study
period.
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Sample Size and Power
The sample sizes for the secondary analyses of colorectal cancer and second
primary cancers (lung, stomach, kidney, bladder, and endometrial cancers) were
restricted by the size of the data set. The population set of CRC cases in the SEERMedicare are 58,171 cases of both genders reported between 2011-2013 (NIH, 2017).
The study was conducted using adequate effect size and statistical power to prevent type
1 and type II errors and to achieve a well representative study that will make the study
attain statistical significance. Since I used secondary data, my sample size was all the
valid cases in the dataset, therefore a priori power analysis is not needed. After the data
analysis, I conducted post hoc power analysis using G*Power calculator (Faul, Erdfelder,
Lang & Buchner, 2007) to confirm that the obtained sample size is adequate.
Instrumentation and Materials
This study used archival data from the Surveillance, Epidemiology, and End
Results (SEER)-Medicare. The SEER- Medicare dataset is the Program of the National
Cancer Institute which provides information on cancer statistics with the intention to
ameliorate the cancer problem in the U.S. SEER-Medicare is a secondary data set
collected using Health Measures, Multidisciplinary Treatment planning (MTP)
questionnaire and Patient-Reported outcomes version of the common terminology criteria
for adverse events (PRO-CTCAE) (National Institute of Health, 2017). Health Measures
also known as the Person-Centered Assessment Resource (PCAR) is created and
validated by National institute of Health (NIH) as an online resource that use four personcentered measurement systems. The Multidisciplinary Treatment Planning (MTP)
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questionnaire is used to provide insight into the different ways on how it’s used for
different kinds of cancers in care delivery organizations to enhance the quality of care
(NIH, 2017).
Reliability of Data
The generalizability of research study to the population hinges on reliability and
validity among researchers using quantitative study (Houser, 2012). SEER-Medicare
ensures the data are reliable by providing a detailed description of research methods,
researcher journal, peer examination of procedures and results, and measures of
instrument reliability (accuracy and consistency of test instrument and results). The
SEER-Medicare database improves data quality and consistency by the centralized
system to manage the data which provides support for all main cancer registry functions,
including data import, linkage, editing, consolidation, and reporting. (Sun & Trinh,
2015).
Validity of Data
Construct validity is to ensure that the study measures that which researchers said
it was intended to measure, or originate the truthfulness of the result (Golafshani, 2003,
Bashir, Tanveer & Azeem 2008). The linkage of the SEER-Medicare data is a joint effort
of the NCI, the SEER registries, and the Centers for Medicare and Medicaid Services
(CMS). The linkage of persons in the SEER data to the Medicare claims was done by
NCI and CMS and not by individual researchers to ensure accuracy and reliable of data
for the appropriate research. The SEER collects 28% of the US. Population’s cancer
incidence and survival data from population-based cancer registries (Sun & Trinh, 2015).
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Quality improvement represents an integral part of the SEER program through routine
audits conducted on many data received from hospitals and external sources (Sun &
Trinh, 2015). The SEER-Medicare administrator reported that the following are how
quality and validity are maintained through numerous checks performed at each step of
the linkage and file preparation; some of the checks include the followin:
1. Compare list of patients received for linkage with Medicare with patients in SEER
file.
2. Compare gender, date of death in SEER and Medicare and remove linked patients
that don't match on gender or have more than 6 months difference in date of
death.
3. Compare counts between linkages, and check that all old patients are in the new
linkage. Investigate missing cases.
4. Track number of claim records received to the number of output records from
each step of the claims processing and to the final records.
5. Calculate rate of claims per patient by claim type and compare the rates produced
for each calendar year.
6. Run sample analysis programs and compare between linkages.
7. Test all extract programs and confirm that patients and their claims from prior
linkages are included in new linkage files.
SEER’s most up to date file has diagnoses from 1973 to 2012, an approximate 8.6 million
cases including 7.8 million malignant cases. The SEER-Medicare contain patient
entitlement and diagnosis summary file (PEDSF) contains Cancer files from SEER that
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include detail like site, morphology, grade, stage and those that matched Medicare
records, including demographic data, Medicare eligibility and coverage, and
socioeconomic data that was gathered by the US Census for the census tract where the
patient lives (Engels et al., 2011). The summarized denominator (SUMDENOM) file has
similar demographic but only 5% of sample Medicare beneficiaries residing in the SEER
areas, chosen randomly using the last 2 digits of their Social Security number (Engels et
al., 2011).
Data Analysis Plan
This study used only secondary data for analysis. There is HIPAA protection for
Data obtained from cancer patients due to confidentiality, and permission was received
before accessing SEER-Medicare data after answering series of questionnaires about the
study over a period of nine months. The dataset was free of the identification of the
patients to prevent compromise of confidentiality. The proposed secondary data for this
study was electronically extracted, cleaned to address miscoded, missing data before
analysis using SPSS (PASW version 25) (Frankfort-Nachmias & Nachmias, 2008). The
reason for using SPSS is due to its ability to handle the analysis of large datasets as well
as provide relevant analysis of statistical tests. The independent variables that I proposed
to use in this study are presented in Table 2:
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Table 2
Variables, Research Questions, and Level of Measurement
Variable name
Second primary cancers
Lung,
Stomach,
Kidney,
Bladder,
Endometrial
Age
Gender
Ethnicity
Alcohol
Smoking
Genetic/Familiar
Metabolic syndrome:
Hypertension
Abdominal obesity
Dyslipidemia
Diabetes
Hypertriglyceridemia
Metabolic Syndrome

Research Question(s)
Role
Level of Measurement
1, 2, 3, 4, 5
Dependent
Categorical

6
6
6

Independent
Independent
Independent
Mediating
Mediating
Mediating

Continuous
Dichotomous
Categorical
Dichotomous
Dichotomous
Categorical

1
2
3
4
5
7

Independent
Independent
Independent
Independent
Independent
Independent

Continuous
Continuous
Continuous
Continuous
Continuous
Dichotomous

Descriptive statistics were calculated for each of the study variables in table 3. I used
frequencies to describe the dichotomous and categorical variables, while the mean and
standard deviation was used for the continuous variables, such as age.
The dependent variable (existence of SPC) was categorical variable with two
levels (yes/no). Binomial logistic regression analysis (BLR) is a statistical technique that
is used to predict the possibility of categorical or binary or dichotomous outcome
variables (Mala, Ravichandran, Raghavan, & Rajmohan, 2010). The independent
variables can be either dichotomous (binary) or continuous (interval or ratio in scale).
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Multicollinearity was evaluated using simple correlations among the independent
variables, and multivariate diagnostics (i.e., standard multiple regression) was used to
assess for multivariate outliers and to exclude of outliers or influential cases
(Starkweather & Moske, 2011).
BLR was the choice for analysis because there is no need for the assumption of
normality, linearity, or homoscedasticity (Starkweather & Moske, 2011). BLR has some
assumptions, like the assumption of independence among the dependent variable choices
which says that a difference exists between the choice of or membership in one category
to another category (dependent variable) (Starkweather & Moske, 2011).
Threats to Internal and External Validity
It is imperative to maintain balance in the control of threats to internal validity
with the need to maximize external validity. The need for research studies to be
generalizable is an important issue, but when the research study has too much external
control, it becomes limited in applicability to the real-world populations (House, 2012). It
is imperative that the research balance every component that gives strength to internal
validity while maintaining a sizeable external validity as possible (Houser, 2012).
SEER-Medicare database is known for standard quality research through the
quality assurance that helps maintain and minimizes threats to internal validity by
ensuring regular quality improvement routine audit (Sun & Trinh, 2015). Also, the threats
to external validity are minimized through the centralized control system (Sun & Trinh,
2015). The SEER site is evaluated pre- and post-implementation of a current redesign.
Also, The SEER-Medicare linked database represent an important national research
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resource that supports studies on cancer patterns of care, quality of cancer care, and costs
of cancer care (National Cancer Institute, 2005). Also, SEER-Medicare ensure quality
data through a three-year cycle for updating the data link in conjunction with extensive
and detailed technical support on SEER-Medicare web page as well as organizing
occasional conferences, workshops, presentations; and publications in the professional
literature (National Cancer Institute, 2005).
In this study, the generalization of the results (external validity) should be done
with caution and it is partly confirmed by the control of confounding using multivariable
analysis.
Ethical Considerations
Ethical consideration is guided by Institutional Review Board (IRB) that reviews
the study protocol, administered questionnaires, discover problems and concerns, and
works with the investigators as needed to improve the study. The IRB guides the
researchers as well as ensure the participant's confidentiality is maintained. I received
approvals from Walden University IRB (#12-04-18-0249165) and the SEER-Medicare
which is source of the dataset.
Summary
In this chapter, I presented the methodology for the proposed study. I used
secondary data analyses using a retrospective study design. The study population
included male and female patients diagnosed with CRC and later develop SPC. The study
intended to involve the use of binomial logistic regression to look for associations to test
the associations between the MetS, its components and SPC among CRC patients,
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controlled for age, gender and race/ethnicity. The results of this study will be presented in
Chapter 4.
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Chapter 4: Results
Introduction
The purpose of this quantitative study was to investigate the association between
MetS, MetS components, gender, race, and age and SPC among patients diagnosed with
CRC. I used 2011 to 2013 secondary data from the SEER-Medicare, obtained from the
study of cancer among the U.S. elderly population (65 years and over; National Institute
of Health, 2017). The SEER-Medicare CRC dataset represents health data collected from
people across a wide spectrum of CRC risk and cover 26% of the U.S population. The
information obtained from SEER-Medicare data included age, gender, race-ethnicity,
MetS components, and any diagnosis of SPC (lung, stomach, endometrial, kidney, and
bladder) among CRC patients over a 5-year period.
The ethical approval to conduct this study was received from Walden University
IRB (approval # 12-04-18-0249165) and the SEER-Medicare (contract #
SRMEDIC/003027), which was the source of the dataset. Approval was received from
SEER-Medicare after about 9 months of scrutiny of the study proposal by SEERMedicare. The complexity of the dataset delayed initiation of study analysis as there was
a need to retrieve and merge several large complex dataset folders of the numerous study
variables.
A change from the initial data analysis plan was necessary. The mediating
variables of smoking, alcohol, and family history of MetS were unavailable or with many
missing cases in the dataset and therefore were not included in the analysis. Also, age
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was changed to a categorical variable from the previously proposed use as a continuous
variable to have a better distribution of the sample by age category.
This chapter includes the presentation of the descriptive statistics for all variables
and the demographic characteristics of the sample. The chapter continues with the
presentation and description of the results of the bivariate analysis between each predictor
and the dependent variable and multivariable analysis between the predictors and the
dependent variable.
Descriptive Analysis of the Sample Population
The epidemiological data included the following independent variables: MetS and
its components (hypertension, obesity, diabetes, hypertriglyceridemia, dyslipidemia), age,
gender, and race. The dependent variable was SPC in CRC (yes/no). The descriptive
statistics are shown in Table 3.
The total study population N =4,217 was characterized by approximate equal male
(50.3%) and female (49.7%) participants. Individuals aged 65 to 75 years-old (68.8%)
were more than participants aged above 75 years (31.2%). Whites (41.7%) were the
predominant race, followed by African Americans (20.1%), Hispanic/Latinos (10.3%),
Asians (8.6%), American Indians/Alaskan natives (7.8%), and Native Hawaiian/other
pacific islanders (6.5%), and 5.0% were unknown. Among the study population, 25.2%
demonstrated MetS, 31.6% had hypertriglyceridemia, 46.6% had dyslipidemia, 21% had
hypertension, and 42.5% of the study population were recorded as obese. In addition,
11.1% of the study population had SPC, and 10.8% were reported to have Type 2
diabetes mellitus.
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Table 3
Descriptive Statistics of the Variables Under Study (N=417)
Variable
Gender
Males
Females
Age (in years)
65-75
>75
Race
White
Black/African American
American Indian/Alaska Native
Asian
Hispanic/Latino
Native Hawaiian/other pacific
islander
Unknown
SPC
Yes
No
MetS
Yes
No
Obesity
Yes
No
Diabetes Mellitus
Yes
No
Hypertension
Yes
No
Dyslipidemia
Yes
No
Hypertriglyceridemia
Yes
No

Frequency

Percent %

2120
2097

50.3
49.7

2900
1317

68.8
31.2

1759
847
331
361
436
272

41.7
20.1
7.8
8.6
10.3
6.5

211

5.0

468
3749

11.1
88.9

1062
3155

25.2
74.8

1794
2423

42.5
57.5

457
3760

10.8
89.2

884
3333

21.0
79.0

1964
2253

46.6
53.4

1332
2885

31.6
68.4
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The RQs and hypotheses of this study are the following:
RQ1: Is there an association between hypertension and SPCs in CRC patients?
Hypotheses
H01: There is no association between hypertension and SPCs in CRC patients.
Ha1: There is an association between hypertension and SPCs in CRC patients.
Research Question 2
RQ2: Is there an association between abdominal obesity and SPCs in CRC
patients?
Hypotheses
H02: There is no association between abdominal obesity and SPCs in CRC
patients.
Ha2: There is an association between abdominal obesity and SPCs in CRC
patients.
Research Question 3
RQ3: Is there an association between dyslipidemia and SPCs in CRC patients?
Hypotheses
H03: There is no association between dyslipidemia and SPCs in CRC patients.
Ha3: There is an association between dyslipidemia and SPCs in CRC patients.
Research Question 4
RQ4: Is there an association between diabetes and SPCs in CRC patients?
Hypotheses
H04: There is no association between diabetes and SPCs in CRC patients.

78
Ha4: There is an association between diabetes and SPCs in CRC patients.
Research Question 5
RQ5: Is there an association between hypertriglyceridemia and SPCs in CRC
patients?
Hypotheses
H05: There is no association between hypertriglyceridemia and SPCs in CRC
patients.
Ha5: There is an association between hypertriglyceridemia and SPCs in CRC
patients.
Research 6
RQ6: Is there an association between age, gender, and ethnicity with SPCs in CRC
patients?
H06: There is no association between age, gender, and ethnicity with SPCs in
CRC
patients
Ha6: There is an association between age, gender, and ethnicity with SPCs in
CRC
patients
RQ7: Is there an association between MetS and SPCs in CRC patients?
Hypotheses
H07: There is no association between MetS and SPCs in CRC patients.
Ha7: There is an association between MetS and SPCs in CRC patients.
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Results
In order to address these RQs, inferential analyses were conducted in two phases.
First, bivariate analysis (chi-square) was conducted for each independent variable and the
outcome variable (SPC; yes/no).
Bivariate Analysis
The results of this analysis are presented in the chi-square Table 4.
Research Question 1. As can be seen in Table 4, out of the total of 468
participants with SPC, 47 (10%) had hypertension compared to 421 participants with no
hypertension but with SPC (90%). There is a significant relationship between no
hypertension and SPC, X2(1, N = 4,217) = 37.9, p < .001. The Cramer’s V (effect size)
for hypertension is weak (V: .095, p < .001). Based on this result, I failed to reject the null
hypothesis, which is no association between hypertension and SPC.
Research Question 2. According to chi square results, there is a significant
relationship between obesity and SPC, X2(1, N = 4,217) = 293.9, p < .001. The Cramer’s
V (effect size) is weak for obesity (V: .264, p < .001). As shown in Table 4, among
participants with SPC, 372 participants were obese (79.5%) while 96 participants (20.5%)
without obesity had SPC. Based on the p value < .001, the association of obesity and SPC
is statistically significant and the null hypothesis is hereby rejected.
Research Question 3. The chi-square analysis about the association of
dyslipidemia with SPC is shown in Table 4. There were 90 participants (19.2%) with
dyslipidemia who had SPC compared to 378 participants (80.8%) with SPC but without
dyslipidemia. There is a significant relationship between no dyslipidemia and SPC, X2(1,
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N = 4,217) = 158.1, p < .001, Cramer’s V (effect size) is weak for dyslipidemia (V:.194, p
< .001); therefore, I failed to reject the null hypothesis, which is no association between
dyslipidemia and SPC.
Research Question 4. Research Question 4 about the association of diabetes with
SPC is shown in the chi square Table 4. Out of the 468 participants with SPC, 24
participants (5.1%) had diabetes compared to 444 with SPC (94.9%) but without
diabetes. There is a significant relationship between no diabetes and SPC, X2(1, N =
4,217) = 17.7, p < .001, Cramer’s V (effect size) is weak for diabetes (V: .065, p < .001);
therefore I failed to reject the null hypothesis, which is no association between diabetes
and SPC.
Research Question 5. The chi-square test about the association of
hypertriglyceridemia with SPC is shown in Table 4. Of the total 1,332 participants with
hypertriglyceridemia, 67 participants (14.3%) had SPC and 401 participants (85.7%) had
SPC without hypertriglyceridemia. There is a significant relationship between no
hypertriglyceridemia and SPC, X2(1, N = 4,217) = 72.6, p < .001. Cramer’s V (effect
size) is weak for hypertriglyceridemia (V: .131, p< .001); therefore, the null hypothesis is
retained, which is no association between hypertriglyceridemia and SPC.
Research Question 6. The chi-square analysis about the association between the
demographics (age, gender, and ethnicity) and SPC is presented in Table 4. Of the three
demographics in this research study, only age was found to have a statistically significant
relationship with SPC. Of the total participants, 65 to 75-year-olds accounted for 84.8%
of participants with SPC compared to 15.2% aged >75 years. This shows that there are
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significantly more participants aged 65 to 75 years who had SPC than those >75 years,
X2(1, N = 4,217) = 63.2, p < .001. The Cramer’s V (effect size) is weak for age (V: .122,
p < .001).
Regarding sex, 246 women (50.4%) with SPC were slightly more than men 232
(49.6%), but this relationship was not significant, X2(1, N = 4,217) = .103, p = .748.
Regarding race/ethnicity (Table 4), Whites were the most populous in the study
with SPC, representing (42.3%) followed by 87 Blacks/Africans (18.7%), 55 Hispanics
(11.8%), 35 Native Hawaiians (7.5%), 35 Native Americans (7.5%), and 24 others
(5.1%). There was no relationship found between race and SPC in this study X2(1, N =
4,217) = 3.65, p = .724.
According to the results above, the null hypothesis for RQ6 is rejected only for
the age variable.
Research Question 7. This is to find out if there is a relationship between MetS
and SPC. According to table 4, 60 participants with MetS (12.8%) had SPC out of a total
of 468 participants with SPC, compared to the 408 of the participants (87.2%) with no
MetS but with SPC, X2(1, N=4217) = 42.7, p < .001, therefore I failed to reject the the
null hypothesis is retained, which is no association between MetS and SPC. The
Cramer’s V (effect size) for MetS is weak (V:.101, p < .001) for MetS.
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Table 4
Bivariate Analysis (Chi-square test) Between Independent and Outcome (SPC)
Variables of the Study
SPC
Independent variables
Total
Age
65-75
>75
Gender
Male
Female
Race
White
Black/African
American
American
Indian/NativeAlaskan
Asians
Hispanic/Latinos
Native
Hawaiian/Other
Pacific Islander
Unknown
MetS
Yes
No
Obesity
Yes
No
Diabetes
Yes
No
Hypertension
Yes
No
Dyslipidemia
Yes
No
Hypertriglyceridemia
Yes
No

Yes
N (%)
468 (11.1)

No
N (%)
3749 (88.9)

Total

397 (84.8)
71 (15.2)

2503 (59.4)
1246 (29.5)

2900
1317

232(49.6)
236(50.4)

1888(50.4)
1861(49.6)

2120
2097

198(42.3)
87(18.6)

1561(41.6)
760(20.3)

1759
847

35(7.5)

296(7.9)

331

34(7.3)
55(11.8)
35(7.5)

327(8.7)
381(10.2)
237(6.3)

361
436
272

24(5.1)

187(5.0)

211

60(12.8)
408(87.2)

1002(26.7)
2747(73.3)

1062
3155

1422(37.9)
2327(62.1)

1794
2423

433(11.5)
3316(88.5)

457
3760

837(22.3)
2912(77.7)

884
3333

1874(50.0)
1875(50.0)

1964
2253

372(79.5)
96(20.5)
24(5.1)
444(94.9)
47(10)
421(90)
90(19.2)
378(80.8)
67(14.3)
401(85.7)

1265(33.7)
2484(66.3)

χ2

p

63.217

.000

.103

.748

3.652

.724

Cramer’s
V

4217

1332
2885

.122

42.706

.000

.101

293.954

.000

.264

17.756

.000

.065

37.888

.000

.095

158.168

.000

.194

72.658

.
.000

.131
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Multivariable Analysis
Additional to bivariate analysis, multiple logistic regression (Binomial Logistic
Regression-BLR) was applied in this study to predict the probability to have SPC based
on the predictors of age, gender, race and obesity (the only MetS component which was
found significant in the bivariate analysis). In order to have valid results from this study,
the study variables are expected to meet the required assumptions of BLR. This study
variables were checked and met the following assumptions; the dependent variable was
dichotomous, there was no multicollinearity, and there were no extreme outliers.
Table 5 displays the Cox & Snell R Square (.086) and Nagelkerke R Square
(.171) values, both referred to as the pseudo R2 value and used to calculate and explain
the extent of change or variation. The variation in the dependent variable based on this
study model ranges from 8.6% to 17.1%, depending on whether the Cox & Snell R2 or
Nagelkerke R2 methods is referenced, respectively.
Table 5
Binary Logistic Regression Model Summary
-2 Log
Cox & Snell Nagelkerke R
Step
likelihood
R Square
Square
a
1
2561.510
.086
.171

The Hosmer and Lemeshow test (Table 6) was conducted to check the fit of
model to the data and p value equal or greater than .05 is considered as good fit. P value
of .049 means there is no evidence of lack of fit,.
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Table 6
Hosmer and Lemeshow Test
Step
Chi-square
df
1
15.542
8

Sig.
.049

The Table 7 below shows the predictors used in this study to predict the
probability of an SPC outcome for a unit change in an independent variable while
keeping other independent variables constant. The result shows that the odds of not
having SPC is 2.9 times greater for individuals aged >75 years compared to those of 6575 years (OR=2.9, 95%CI: 2.2-3.8). Also, the odds of not having SPC is 6.5 times greater
for not obese individuals compared to obese individuals (OR=6.5, 95%CI: 5.2-8.3).
According to the results above null hypothesis for RQ2 and 6 were rejected.
In addition, using the lowest significant OR (2.9) as effect size, I conducted post
hoc power analysis using regression analysis; the achieved statistical power was found
satisfactory 0.99>0.80 (G*Power Calculator).
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Table 7
Binary Logistic Regression to Predict non having SPC Having as Predictors Age, Race, Gender and Obesity
95% C.I.
for Odds Ratio
Odds*
B
S.E.
Wald
df p
Ratio
Lower
Upper
>75 years (ref. 65-75 y) 1.060
.137 59.478
1 .000
2.886
2.204
3.778
Race (ref. White).
6.213
6 .400
Black or African
.192
.142
1.814
1 .178
1.211
.916
1.601
Americans
American Indian or
.054
.203
.071
1 .790
1.056
.708
1.573
Alaskan Native
Asian
.128
.205
.388
1 .533
1.136
.760
1.697
Hispanic/Latino
-.191
.172
1.225
1 .268
.826
.590
1.158
Native Hawaiian or
-.230
.208
1.228
1 .268
.794
.529
1.193
other Pacific /islander
Unknown
.096
.240
.159
1 .690
1.100
.687
1.763
Female (ref. male)
-.124
.103
1.439
1 .230
.883
.721
1.082
No obesity (ref. yes)
1.876
.120 242.469
1 .000
6.525 5.153
8.262
Constant
1.124
.101 123.248
1 .000
3.076
*For odds ratio interpretation, SPC outcome is considered as “non having SPC”.

Summary
The total study population N (4217) is characterized by an approximate equal
male (50.3%), and female (49.7%) participants. Individuals aged 65-75 years-old (68.8%)
were more than the ones aged above 75 years (31.2%). Whites (41.7%) were the
predominant race, and 25% of the participants demonstrated MetS, 31.6% had
hypertriglyceridemia, 46.6% dyslipidemia, 21% hypertension, and 42.5% of the study
population were recorded as obese. In addition, 11.1% of the study population had SPC,
and 10.8% were reported to have type 2 diabetes mellitus. According to BLR results, the
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odds of not having SPC is 2.9 times greater for individuals aged >75 years compared to
those of 65-75 years (OR=2.9, 95%CI: 2.2-3.8). Also, the odds of not having SPC is 6.5
times greater for not obese individuals compared to obese individuals (OR=6.5, 95%CI:
5.2-8.3).
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
There are limited data on the association of MetS and the SPC among CRC
patients of varying ages, genders, and race/ethnic groups in the United States. However,
studies have revealed that a person diagnosed with CRC irrespective of the mode of
treatment has an increased risk of developing SPC compared to the general population
(Donin et al., 2016; Lee et al., 2015). It was reported that 55% of cancer survivors with
SPC will die from the SPC (Donin et al., 2016). The role of MetS, age, gender, and
ethnicity in increasing the risk of a diagnosis of SPC with CRC has been investigated but
needs further clarification because researchers have examined the SPC relationship with
other risk factors except MetS (Dasguta et al., 2012; Lee et al., 2016; Raj et al., 2014).
Data are indicating that the risk for developing an SPC may be significant for patients
already diagnosed with CRC (Dasgupta et al., 2012; Oritz-Mendoza & De la Fuente-vera,
2014).
The purpose of this quantitative study was to examine whether a relationship
exists between MetS (including its components: obesity, diabetes, hypertension,
dyslipidemia, and hypertriglyceridemia), ethnicity, gender, and age, and the SPC of
colorectal cancer like lung, endometrial, stomach, kidney, endometrial, and bladder
cancers, among individuals diagnosed with CRC. In Chapter 5, I will start with a brief
review of the key findings of the study. I will follow this with a detailed interpretation of
the findings as related to existing literature, my theoretical framework, and the study
population. I will present the limitations of the study in terms of generalizability and/or
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trustworthiness, validity, and reliability. Finally, I will provide recommendations for
further research and practice and discuss the implications for social change based on my
research conclusions.
Key Findings of the Study
The sample size of the study was 4,217 patients with CRC. According to the
results of the study, 25% of the participants demonstrated MetS, 31.6% had
hypertriglyceridemia, 46.6% had dyslipidemia, 21% had hypertension, and 42.5% of the
study population was recorded as obese. In addition, 11.1% of the study population had
SPC, and 10.8% were reported to have Type 2 diabetes mellitus. BLR revealed that the
odds of not having SPC is 2.9 times greater for individuals aged >75 years compared to
those of 65 to 75 years (OR = 2.9, 95% CI: 2.2-3.8). Also, the odds of not having SPC is
6.5 times greater for not obese individuals compared to obese individuals (OR = 6.5, 95%
CI: 5.2-8.3). There was no statistically significant relationship between gender, race,
MetS, hypertension, dyslipidemia, hypertriglyceridemia, diabetes, and SPC.
Interpretation of the Findings
Demographics
Age. The finding of this study was that the odds of not having SPC is 2.9 times
greater for individuals aged >75 years compared to those between 65 and 75 years. This
can be partly explained by the fact that age <75 years is associated with the increasing
risk of nongenetic cancer due the accumulative effect of UV radiation from the sun,
smoking, an unhealthy diet, and dysregulation of the immune response over time,
resulting in normal cell division to start mutation (Campisi, 2013; Deeks, 2011; NCI,
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2015; White et al. 2014). Furthermore, the findings of this study are in accordance with
previous research, which revealed that the median age for diagnosis of CRC is 68 years
and the median age for cancer diagnosis is 66 (NCI, 2015). Thus, individuals with >75
years may have exceeded the median age of most cancers; hence, the odds of having SPC
reduces as the age increases. This study confirms previous findings in literature; for
example, Lee et al. (2015) reported that younger CRC patients (< 40 years) had a higher
risk of SPC compared to their older counterparts. I aimed to exclude CRCs of genetic
origin from the study by using age 65 as an inclusion criterion to enable better
examination of the relationship between MetS and SPC; on the other hand, Donin et al.
(2016) used age <18 for an exclusion criterion. Further research is needed to investigate
the relationship between age and SPC among CRC cancers by including CRC cases of
hereditary/genetics etiology as the primary cancers and can cause also SPC (Donin et al.,
2016).
Gender. Gender had no statistically significant relationship with the development
of SPC in my study. This finding does not agree with the study of Donin et al. (2016),
who found that White men were more likely to develop SPC, but among 66 to 80-yearold patients, the risk in women was higher than the men. Ortiz-Mendoza et al. (2016)
investigated the relationship between obese women with MetS and SPC and found that
MetS in female cancer survivors may be a risk factor for a SPC. On the other hand, Park
et al. (2016) found that males have a stronger BMI-cancer association in prediagnosed
obese participants compared to females. However, some studies reported that females
have a greater risk of developing SPC (Emory Winship Cancer Institute, 2016; Jong,
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2015; Raj et al., 2011; Singh et al., 2012). Due to these contradictory results, further
research is needed to explore the impact of gender on SPC, especially among CRC
patients.
Ethnicity/race. Ethnicity/race was not found to be significant in this study, and
this finding was supported by the study by Raj et al. (2011), who concluded that
race/ethnicity is not known to be predictive of SPC. It is pertinent to say that
race/ethnicity has been inconsistent in the outcome with SPC development in different
studies and geographic locations; for example. Jian et al. (2013) found an association
between lung adenoma (SPC) and CRC in both sexes in cross-township correlations
(within the same country) but not in cross-country comparisons (in which there are
different races/ethnicities). This geographic location inconsistency might be associated
with the possibility of potential risk factors related to the patient's location such as
different dietary behaviors and cultures.
MetS and MetS Components
Obesity. According to the results of this study, the absence of obesity resulted in
6.5 greater odds of not developing SPC. This is because a nonobese person is protected
from problems associated with obesity. There is a connection of obesity as risk factors to
many disease entities, including cancers (Meijers & De Boer, 2019; Ortiz-Mendoza et al.,
2016; Stone, McPherson, & Darlington, 2018). Previous researchers have described the
involvement and association of obesity with the pathophysiology of hypertension,
diabetes mellitus, dyslipidemia, and hypertriglyceridemia (Park et al., 2016). The finding
of obesity as a risk factor for SPC in my study is similar to the studies by Gibson et al.
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(2014; n = 224; overweight HR, 1.39; 95% CI, 1.01 to 1.92; obese HR, 1.47; 95% CI,
1.02 to 2.12; per 5-unit change in BMI HR, 1.12; 95% CI, 0.98 to 1.29) and Jung et al.
(2019), who reported that obese female cancer survivors had a higher risk of overall SPC
(aHR, 1.17; 95% CI, 1.04‐1.32). There has been an established link in the literature by
animal experiments that obesity and cancer can been modified by dietary means
(Nogueira et al., 2012a; Nogueira et al., 2012b). Nonobese individuals are excluded from
problems potentiated by obesity and are unlikely to develop SPC. A patient who has been
counseled to practice lifestyle behavioral modification is encouraged to adopt a
nonsedentary lifestyle, perform regular exercise, and adopt a healthy diet to curtail
excessive weight gain that can result in the development of other associated risk factors
of MetS (Park et al., 2016).
MetS. I did not find a positive association between MetS and SPC, and this result
did not agree with the study of Ortiz-Mendoza and De la Fuente-Vera (2014). OrtizMendoza and De la Fuente-Vera found that a high prevalence of obesity among Mexican
women population accounted for the MetS observed among cancer survivors. The results
of my study on MetS may be attributed to two main factors: First, I did not investigate the
possible role of the primary cancer subsite in the colon or rectum that could predict the
type and sites of SPC that could also be related to MetS (see Lee et al., 2015; Raj et al.
2011; Stone et al., 2018). Secondly, my study was restricted to only five cancer types
SPC of CRC, but Lee et al. (2015) stated that patients having CRC was found to be
statistically significant for all cancers. Some of the above-mentioned cancers are not
represented in my study, like the uterus, thyroid, breast, ovaries, and prostate cancers,
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which are also associated with SPC of CRC (see American Cancer Society, 2020; Lee et
al., 2015; Yang et al., 2017). This could explain the weak association obtained for the
MetS and its components due to a possible masking effect obtained from the absence of
other cancers that were not tested in my study.
Hypertension. Hypertension had no significant association with SPC in my study
but Oritz-Mendoza et al (2016) and Emory Winship Cancer Institute, (2016) found that
hypertension is a risk factor for SPC and primary cancers, respectively. Seretis, Cividini,
Markozannes et al. (2019) found a positive association between hypertension and breast,
esophageal adenocarcinoma and squamous cell carcinoma, liver cancers but these cancers
were not examined in my study thus partly accounting for the lack of association obtained
in my study.
Diabetes. This study found no association between diabetes and SPC. However,
the study by Lee et al. (2015) has described diabetes as one of the risk factors for SPC
development. Diabetes has been associated with other cancers like postmenopausal
breast, pancreatic, liver, and non-Hodgkin’s lymphoma (Collins, 2014; Giovannucci et
al., 2010) which are excluded in my study. The exclusion of these cancers could account
the lack of association obtained in my study.
Hypertriglyceridemia. I did not obtain a statistically significant association
between hypertriglyceridemia and SPC. Hypertriglyceridemia has been associated with
other cancers like thyroid, prostate, and gynecological cancers (Ulmer et al. 2009) which
were not included in my study.
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Dyslipidemia. In my study, I did not find a significant association between
dyslipidemia and SPC but the study by Lee et al (2015) found a significant association.
Dyslipidemia has been associated with cancer such as breast, non-small cell lung cancer,
and prostate cancer and these cancers were not included in my analysis.
A more robust study containing all possible cancer associations with MetS
components is an important suggestion for future study.
Limitations of the Study
This study was limited to the data available in the dataset. It would have been
better to get a wider spread of data from the 50 US states, with larger sample and more
types of SPC but the such raw data can be very complex and might take considerable
time and resources to extract them. Also, I intended to study the covariates/potential
confounders of alcohol, smoking, family history and diet but the received data did not
include this information. There might have been selection bias as there was no equal
representation of race in the data so to have a more representative sample of the national
population with CRC and its possible to have gotten more participants from one region
than the other and that could affect the outcome. Also, there was limited availability of
study literature to compare my results.
Further, the use of the dependent variable as yes/no could make it difficult to
know which of the SPC was being tested. It was impossible to get additional information
about subjects in the cohorts, such as other genetic or non-genetic risk factors.
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Recommendations
Future studies that examine MetS and SPC in different populations in United
States and globally could include potentially important confounders for cancer, such as
alcohol, smoking, dietary/nutritional status, chemotherapy/ radiation therapy. In addition,
the inclusion of as many SPC cancer types as possible in future investigations on this
topic can result in more reliable associations between the predictors and the outcome. The
alternative study methodology that I would suggest is the mixed-method study design
which can provide additional information on factors that influence the SPCs such as
attitudes and beliefs of clinicians and CRC patients regarding screening for SPCs. The
findings of the study have the potential implications of enabling early surveillance and
screening for SPC among high-risk elderly and obese CRC patients. Furthermore, more
studies are needed to further investigate the impact of demographics and MetS
components on several types of SPC, thus, to have more reliable results on these potential
associations.
Implications for Social Change
This study advanced the understanding of the association between MetS and SPCs
(lung, endometrial, stomach, kidney, and bladder cancers) in CRC patients. The
importance of early surveillance, detection, and treatment of SPC in CRC patients is
significant to achieve better survival rates. My result of a positive association between
obesity and age and SPC will be helpful to clinicians by providing treatment algorithms
and surveillance for early screening/testing for SPC among CRC patients especially those
who are elderly and obese in the populations. It also educates the susceptible elderly and
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obese population and their family on SPC. Obesity is a silent pandemic and the
adjustment of diet, physical exercise/ weight loss, and healthier behaviors can help to
reduce the incidence of SPC in the population.
This study can promote positive social change by enhancing clinicians’ and public
health policy makers’ understanding of the relationship between age, obesity-induced
MetS and SPCs in CRC patients. This study can also highlight the need for early
introduction of a surveillance program for detection of SPC in CRC survivors by health
care and public health professionals and it demonstrates the importance of early
intervention in mitigating SPC morbidity and mortality rate.
Conclusion
In this study, the development of SPC has been investigated among CRC patients
after diagnosis, or treatment. There is no substantial evidence of the role of MetS in the
increasing incidence of SPC among CRC patients. This study filled a gap in the literature
on the association of MetS and SPCs of CRC patients. Early detection of cancer remains
one of the most valuable interventions to improve health outcomes. A greater
understanding of the components of MetS and its association with SPC will enhance
positive social change through a reduction in morbidity and mortality among CRC
patients that might develop SPC of lung, endometrial, stomach, kidney, and bladder
cancers. I found that CRC patients who were aged 65-75 years (OR=2.9, 95%CI: 2.2-3.8)
and obese (OR=6.5, 95%CI: 5.2-8.3) had more odds to develop SPC. These data provide
important information for surveillance target groups for risk assessment and therapy and
enable clinicians to develop the most effective treatment algorithm for CRC patients.
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Although this study does not include all possible covariates, it provides valuable
information that can be used to prevent SPC cases in this high-risk population.

97
References
Agouridis, A. P., Rizos, C. V., Elisaf, M. S., & Filippatos, T. D. (2013). Does
combination therapy with statins and fibrates prevent cardiovascular disease in
diabetic patients with atherogenic mixed dyslipidemia? The Review of Diabetic
Studies, 10(2-3), 171–190. http://doi.org/10.1900/RDS.2013.10.171
Ahmed, F., Goodman, M. T, & Kosary, C. (2006). Excess risk of subsequent primary
cancers among colorectal cancer survivors. 1975-2001. Cancer, 107(5), 11621171. doi:10.1002/cncr.22013.4
Ahmed, R. L., Schmitz, K. H., Anderson, K. E., Rosamond, W. D., & Folsom, A. R.
(2006). The metabolic syndrome and risk of incident colorectal cancer. American
Cancer Society Journal Cancer, 107(1), 28-36.
https://doi.org/10.1002/cncr.21950
American Cancer Society. (2017a). Understanding your pathology report: Invasive
adenocarcinoma of the colon. Retrieved from
https://www.cancer.org/treatment/understanding-yourdiagnosis/tests/understanding-your-pathology-report/colon-pathology/invasiveadenocarcinoma-of-the-colon.html
American Cancer Society. (2017b). What is colorectal cancer? Retrieved from
https://www.cancer.org/cancer/colon-rectal-cancer/about/what-is-colorectalcancer.html
American Diabetes Association. (2013). Standards of medical care in diabetes—2013.
Diabetes Care, 36(1), S11–S66. http://doi.org/10.2337/dc13-S011

98
American Heart Association. (2004). Definition of metabolic syndrome. Circulation,
109,433-438. https://doi.org/10.1161/01.CIR.0000111245.75752.C6
Bashir, M., Tanveer, M. A., & Azeem, M. (2008). Reliability and validity of qualitative
and operational research paradigm. Pakistan Journal of Statistics and Operation
Research, 4(1), 4. doi:10.18187/pjsor.v4i1.59
Boroughs, L. K., & DeBerardinis, R. J. (2015). Metabolic pathways promoting cancer
cell survival and growth. Nature. Cell Biology, 17, 351-359. doi:10.1038/ncb3124
Braun, S., Bitton-Worms, K., & LeRoith, D. (2011). The link between the metabolic
syndrome and cancer. International Journal of Biological Sciences, 7(7),10031015. Retrieved from www.ncbi.nlm.nih.gov/pmc/articles/PMC3164150
Campisi, J. (2013). Aging, cellular senescence, and cancer. Annual Review of Physiology,
75, 685–705. https://doi.org/10.1146/annurev-physiol-030212-183653
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003). Overweight,
obesity, and mortality from cancer in a prospectively studied cohort of U.S.
adults. New England Journal of Medicine, 348(17), 1625–1638.
doi:10.1056/NEJMoa021423
Centers for Disease Control and Prevention. (2016). Overweight and obesity. Retrieved
from www.cdc.gov
Center for Public Education. (2017). How can I know if a data source is trustworthy?
Retrieved from http://www.data-first.org/questions/how-can-i-know-if-a-datasource-is-trustworthy/
Collins, K. K. (2014). Diabetes-cancer link. Diabetes Spectrum, 27(4), 276-

99
280.https://doi.org/10.2337/diaspect.27.4.276
Dasgupta, P., Youlden, D. R., & Baade, P. D. (2012). Multiple primary cancers among
colorectal cancer survivors in Queensland, Australia, 1996-2007. Cancer Causes
Control, 23, 1387-1398.
Deeks, S. G. (2011). HIV infection, inflammation, immunosenescence, and aging. Annual
Review Medicine, 62(1),141–155. doi:10.1146/annurev-med-042909-093756
De Haas, E. C., Oosting, S. F., Lefrandt, J. D., Wolffenbuttel, B. H. R., Sleijifer, D. T. H.
& Gietema, J. A. (2010). The metabolic syndrome in cancer survivors. The Lancet
Oncology,11(2), 193-203. http://dx.doi.org/10.1016/S1470-2045(09)70287-6
Donin, N. C. Filson, A., Drakaki, H. J., Tan, A., Castillo, L., Kwan, et al. (2016). Risk of
second primary malignancies among cancer survivors in the United States, 1992
through 2008. Cancer 122, 3075– 3086.
Enblad, P. (1990). The risk of subsequent primary malignant diseases after cancer of the
colon and rectum. Cancer, 65, 2091-2100. doi:10.1002/10970142(19900501)65:9<2091:AID-CNCR2820650934>3.0.CO;2-M
Engels, E. A., Pfeiffer, R. M., Ricker, W., Wheeler, W., Parsons, R., & Warren, J. L.
(2011). Use of surveillance, epidemiology, and end results-Medicare data to
conduct case-control studies of cancer among the U.S. elderly. American Journal
of Epidemiology, 174(7), 860–870. http://doi.org/10.1093/aje/kwr146
Esposito, K., Chiodini, P., Capuano, A. Bellastella, G., Maiorino, M.I., Rafaniello,
C,…Giugliano, D. (2013). Colorectal cancer association with metabolic syndrome
and its components: a systematic review with meta-analysis.

100
Endocrine, 44(3), 634-647. https://doi.org/10.1007/s12020-013-9939-5
Esposito, K., Chiodini, P., Colao, A., Lenzi, A. & Giugliano, D. (2012). Metabolic
syndrome and risk of cancer. Diabetes Care, 35(11). 2402-2411.
doi.org/10.2337/dc12-0336.
Evans, H.S., Moller, H., Robinson, D., Lewis, C.M., Bell, C.M.J. & Hodgson, S.V.
(2002). The risk of subsequent primary cancers after colorectal cancer in
southeast England. Gut, 50(5), 647-652. doi:10.1136/gut.50.5.647.
Eyvazzadeh & Reilly Colon and Rectal Center, (N.D). Colorectal Cancer. Retrieved from
http://www.ercrc.com/Colorectal%20Cancer.htm
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007). G*Power 3: A flexible
statistical power analysis program for the social, behavioral, and biomedical
sciences. Behavior Research Methods, 39, 175-191.
Gibson, T. M., Park, Y., Robien, K., Shiels, M. S., Black, A., Sampson, J. N., Purdue, M.
P., Freeman, L. E., Andreotti, G., Weinstein, S. J., Albanes, D., Fraumeni, J. F.,
Jr, Curtis, R. E., Berrington de Gonzalez, A., & Morton, L. M. (2014). Body mass
index and risk of second obesity-associated cancers after colorectal cancer: a
pooled analysis of prospective cohort studies. Journal of clinical oncology,
32(35), 4004–4011. https://doi.org/10.1200/JCO.2014.56.8444
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel,
L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010). Diabetes and cancer: a
consensus report. Diabetes care, 33(7), 1674–1685. https://doi.org/10.2337/dc100666A

101
Guan, X; Jin, Y; Chen, Y; Jiang, Z; Liu, Z; Zhao, Z….Wang, X (2015). The Incidence
Characteristics of Second Primary Malignancy after Diagnosis of Primary Colon
and Rectal Cancer: A Population Based Study. PLOS.
https://doi.org/10.1371/journal.pone.0143067
Haggar, F.A. & Boushey, R.P. (2009). Colorectal cancer epidemiology: Incidence,
mortality, survival, and risk factors. Clinics in Colon and Rectal Surgery, 22(4),
191-197. Doi: 10.1055/s-0029-1242458.
Hao, B., Yu, M., Sang, C., Bi, B., & Chen, J. (2018). Dyslipidemia and non-small cell
lung cancer risk in Chinese population: a case-control study. Lipids in health and
disease, 17(1), 278. https://doi.org/10.1186/s12944-018-0925-z
Hardy, O. T., Czech, M. P., & Corvera, S. (2012). What causes the insulin resistance
underlying obesity? Current Opinion in Endocrinology, Diabetes, and Obesity,
19(2), 81–87. http://doi.org/10.1097/MED.0b013e3283514e13
Hemminki, K., Li, X., & Dong, C. (2001). Second primary cancers after sporadic and
familial colorectal cancer. Cancer Epidemiology Biomarkers and Prevention, 10,
793-798. Retrieved from http://cebp.aacrjournals.org/content/10/7/793.
Houser, J. (2012). Nursing research: Reading, using and creating evidence (2nd
ed.).Sudbury, MA: Jones and Bartlett.
Hu, F.B., Manson, J.E., Liu ,S., Hunter, D., Colditz, G.A., Michels, K.B., Speizer, F.E.,
& Giovannucci, E. (1999). Prospective study of adult onset diabetes mellitus
(type 2) and risk of colorectal cancer in women. Journal of National Cancer
Institute, 91(6),542–547. Retrieved from

102
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/10088625/citedby/?tool=pubme
d
Jain, S., Gautam, V., & Naseem, S. (2011). Acute-phase proteins: As diagnostic tool.
Journal of Pharmacy and Bioallied Sciences, 3(1), 118–127.
http://doi.org/10.4103/0975-7406.76489
Jasperson, K.W., Tuohy, T.M., Neklason, D.W. & Burt, R.W. (2010). Hereditary and
familial colon cancer. Gastroenterology,138 (6), 2044-2058. doi:
http://dx.doi.org/10.1053/j.gastro.2010.01.054.
Kim HA, Lee SY, Kwon HS, Lee SH, Jung MH et al. (2013) Gender differences in the
association of insulin resistance with metabolic risk factors among Korean
adolescents: Korea National Health and Nutrition Examination Survey 20082010. Diabetes Research and Clinical Practice, 99, 54-62.
doi:https://doi.org/10.1016/j.diabres.2012.10.011
Jian, Z.H., Lung, C.C., Huang, J.Y., Su, S.Y., Ho, C.C., Chiang, Y.C., & Liaw, Y.P.
(2013). Sex Disparities in the Association of Lung Adenocarcinoma with
Colorectal Cancer. Journal of Cancer, 4(9), 691–696.
http://doi.org/10.7150/jca.7269
Johnson, C. M., Wei, C., Ensor, J. E., Smolenski, D. J., Amos, C. I., Levin, B., & Berry,
D. A. (2013). Meta-analyses of Colorectal Cancer Risk Factors. Cancer Causes &
Control : CCC, 24(6), 1207–1222. http://doi.org/10.1007/s10552-013-0201-5
Johnson, J. R., Lacey, J. V., Lazovich, D., Geller, M. A., Schairer, C., Schatzkin, A., &
Flood, A. (2009). Menopausal hormone therapy and risk of colorectal cancer.

103
Cancer epidemiology, biomarkers & prevention, 18(1), 196–203.
http://doi.org/10.1158/1055-9965.EPI-08-0596.
Jong, R.J (2015). Study Finds High Prevalence of Metabolic Syndrome in U.S. Retrieved
fromhttp://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2015.4260.
Jung, S. Y., Kim, Y. A., Jo, M., Park, S. M., Won, Y. J., Ghang, H., Kong, S. Y., Jung,
K. W., & Lee, E. S. (2019). Prediagnosis obesity and secondary primary cancer
risk in female cancer survivors: A national cohort study. Cancer medicine, 8(2),
824–838. https://doi.org/10.1002/cam4.1959
Meijers, W.C & de Boer, R.A. (2019). Common risk factors for heart failure and cancer,
Cardiovascular Research, 15 (5), 844–853, https://doi.org/10.1093/cvr/cvz035
Kanagasabai, T., Nie, J.X., Mason, C. & Ardern, C.I. (2014). Metabolic syndrome and
prevalent any-site, prostate, breast and colon cancers in the U.S. adult population:
NHANES 1999-2010. Journal of Metabolic Syndrome, 3,135. Doi: 10.4172/21670943.1000135.
Kameyama, M.D. (2009). Second primary cancer in patients with colorectal cancer after
a curative resection. Digestive Surgery, 26, 400-405. doi:10.1159/000229991
Kim, H; Lee, J; Kim, J; Park, H; Oh, H.S; Lee, W.J; Kim, E.A, & Jung, H.K (2013).
Effects of a health education program based on social cognitive theory on the
health promotion of university students with metabolic syndrome. Journal of
Korean Academy of Community Health Nursing, 24(4),451-460.
https://doi.org/10.12799/jkachn.2013.24.4.451
Madeira, F.B, Silva, A.A, Veloso, H.F, Goldani, V.M, Kac, G, Crdoso, V.C, Bettiol, H &

104
Barbieri, M.A (2013). Normal Weight Obesity Is Associated with Metabolic
Syndrome and Insulin Resistance in Young Adults from a Middle-Income
Country. PLoS ONE, 8(3): e60673. https://doi.org/10.1371/journal.pone.0060673
Mastalier, B., Tihon, C., Ghiţă, B., Botezatu, C., Deaconescu, V., Mandisodza, P.,
Drăghici, C., … Simion, S. (2012). Surgical treatment of colon cancer: Colentina
surgical clinic experience. Journal of medicine and life, 5(3), 348-53.
Marley, A. R., & Nan, H. (2016). Epidemiology of colorectal cancer. International
Journal of Molecular Epidemiology and Genetics, 7(3), 105–114. Retrieved from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069274/
Markman, M. & Luce, R. (2010). Impact of the cost of cancer treatment: An internetbased survey. Journal of Oncology, 6 (2), 69-73. doi: 10.1200/JOP.091074.
Mayo clinic. (2016). Lung cancer. Retrieved from mayoclinic.org.
Moran, A.E, Odden, M.C, Thanataveerat, A, Tzong, K.Y,Rasmussen, P.W, Guzman,
D….Goldman, L (2015). Cost-Effectiveness of Hypertension Therapy According
to 2014 Guidelines. New England Journal of Medicine, 372,447-455 DOI:
10.1056/NEJMsa1406751
Mouhayar, E., & Salahudeen, A. (2011). Hypertension in cancer patients. Texas Heart
Institute journal, 38(3), 263–265.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113122/
National Cancer Institute, (2005). 2005 Overview and Highlights. Retrieved from
https://cancercontrol.cancer.gov/bb/2005_bb.pdf
National Cancer Institute, (2017). Metastatic Cancer. Retrieved from

105
https://www.cancer.gov/types/metastatic-cancer
Moore, J. X, Chaudhary, N, & Akinyemiju, T. (2017). Metabolic Syndrome Prevalence
by Race/Ethnicity and Sex in the United States, National Health and Nutrition
Examination Survey, 1988–2012. Preventing Chronic Disease, 14, E24.
http://doi.org/10.5888/pcd14.160287
National Institute of Health, (2017). Healthcare Delivery Research Program. Retrieved
from https://healthcaredelivery.cancer.gov/mtp/
National Institute of Health, (2017). Healthcare Delivery Research Program: SEERMedicare: Number of Cases for Selected Cancers Appearing in the Data.
Retrieved from
https://healthcaredelivery.cancer.gov/seermedicare/aboutdata/cases.html
National Institute of Health, (2018). Healthcare Delivery Research Program: Measures
that are Limited or not Available in the Data. Retrieved from
https://healthcaredelivery.cancer.gov/seermedicare/considerations/measures.html
Ng, A.K & Travis, L.B (2008). Second primary cancers: an overview. Hematolology
Oncolology Clinics of North America, 22(2),271-289. doi:
10.1016/j.hoc.2008.01.007.
Noura, S.A., Ohue, M.A., Seki, Y.A., Tanaka, K.A., Motoori, M.A., Kishi, K.A., &.
Laerd dissertation. (2012). Simple random sampling. Retrieved from
http://dissertation.laerd.com/simple-random-sampling.php.
LaMorte, W.W. (2016). The Social Cognitive Theory. Retrieved from
http://sphweb.bumc.bu.edu/otlt/MPH-

106
Modules/SB/BehavioralChangeTheories/BehavioralChangeTheories5.html
Larsson S.C. & Wolk A. (2007). Obesity and risk of non-Hodgkin’s lymphoma: A metaanalysis. International Journal Cancer,121,1564–1570. doi: 10.1002/ijc.22762.
Lee, Y., Liu, C., Hu, Y., Teng, C., Tzeng, C., Yeh, C., Yen, C. (2015). Incidence of
second primary malignancies following colorectal cancer: A distinct pattern of
occurrence between colon and rectal cancers and association of co-morbidity with
second primary malignancies in a population-based cohort of 98,876 Patients in
Taiwan. Medicine, 94(26)1079. Doi: 10.1097/MD.0000000000001079.
Lee, J., Shin, A., Oh, J. H., & Kim, J. (2017). Colors of vegetables and fruits and the risks
of colorectal cancer. World Journal of Gastroenterology, 23(14), 2527–2538.
http://doi.org/10.3748/wjg.v23.i14.2527
Leveridge, M.J. & Jewett, M.A.S. (2011). Recent development in kidney cancer.
Canadian Urological Association Journal, 5(3),195-203. doi:10.5489/cuaj.10148.
Li-Chu, S., Yi-Yun, T., Su-Mien, L., Tang-Yu, L., Ying-Ling, S., Se-Fen, C., & JawYuan, W. (2014). Clinical characteristics of second primary cancer in colorectal
cancer patients: the impact of colorectal cancer or other second cancer occurring
first. World Journal of Surgical Oncology 12,73. DOI: 10.1186/1477-7819-12-73
Liu M, Wang J, Jiang B, Sun D, Wu L, Yang S, et al. (2013) Increasing Prevalence of
Metabolic Syndrome in a Chinese Elderly Population: 2001–2010. PLoS ONE,
8(6): e66233. https://doi.org/10.1371/journal.pone.0066233
Lopez, M.L., Lana, A., Diaz, S., Fogueras, M.V., Sanchez, L., Comendador, M.A.…
Cueto, A. (2009): Multiple primary cancer: an increasing health problem.

107
Strategies for prevention in cancer survivors. European Journal of Cancer Care,
18, 598-605. 10.1111/j.1365-2354.2008.00974.x.
Ortiz-Mendoza, C & De la Fuente-Vera, T. (2014). Obesity and components of metabolic
syndrome in Mexican women survivors of cancer. Revista Medica Del Instituto
Mexicano Del Seguro Social,52 (5), 588-593. Retrieved from
http://eds.a.ebscohost.com.ezp.waldenulibrary.org/eds/detail/detail?vid=3&sid=cf
c3eeb5-3db7-4fc7-b0cb
65ad4734928d%40sessionmgr4008&hid=4208&bdata=JnNpdGU9ZWRzLWxpd
mUmc2NvcGU9c2l0ZQ%3d%3d#AN=25301134&db=mnh
Ortiz-Mendoza, C., Pérez-Chávez, E, & De-la Fuente-Vera, T. (2016). Modified
metabolic syndrome and second cancers in women: A case control study. South
Asian Journal of Cancer, 5(4),189–191. doi: 10.4103/2278-330X.195341
Pais, R., Silaghi, H., Silaghi, A.C., Rusu, L., & Dumitrascu, D.L. (2009). Metabolic
syndrome and risk of subsequent colorectal cancer. World Journal of
Gastroenterology, 15(4), 5141-5148. doi: 10.3748/wjg.15.5141
Phipps, A.I., Chan, A.T., & Ogino, S. (2013). Anatomic subsite of primary colorectal
cancer and subsequent risk and distribution of second cancers. Cancer, 119, 31403147. doi:10.1002/cncr.28076.
Pothiwala, P., Jain, S.K., & Yaturu, S. (2009). Metabolic syndrome and cancer.
Metabolic syndrome and related disorder, 7(4), 279-287.
doi:10.1089/met.2008.0065.
Raj, K. P., Taylor, T. H., Wray, C., Stamos, M. J., & Zell, J. A. (2011). Risk of second

108
primary colorectal cancer among colorectal cancer cases: A population-based
analysis. Journal of Carcinogenesis, 10, 6. http://doi.org/10.4103/14773163.78114
Rigo, J.C, Vieira, J. L, Dalacorte, R.R, & Reichert, C.L (2009). Prevalence of metabolic
syndrome in an elderly community: comparison between three diagnostic
methods. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/19838483
Riihimäki, M, Hemminki, A, Sundquist, J & Hemminki, K (2016). Patterns of metastasis
in Colon and Rectal cancer. Scientific Reports. 6, 29765.
http://dx.doi.org/10.1038/srep29765.
Roberts, C. K., Hevener, A. L., & Barnard, R. J. (2013). Metabolic Syndrome and Insulin
Resistance: Underlying Causes and Modification by Exercise Training.
Comprehensive Physiology, 3(1), 1–58. http://doi.org/10.1002/cphy.c110062
Seretis, A., Cividini, S., Markozannes, G. et al. (2019). Association between blood
pressure and risk of cancer development: a systematic review and meta-analysis
of observational studies. Scientific Reports, 9, 8565. Doi:
https://doi.org/10.1038/s41598-019-45014-4.
Shen, Y., Wang, C., Ren, Y., & Ye, J. (2018). A comprehensive look at the role of
hyperlipidemia in promoting colorectal cancer liver metastasis. Journal of
Cancer, 9(16), 2981–2986. https://doi.org/10.7150/jca.25640
Siegel, R., Desantis, C. & Jemal, A. (2013). Colorectal cancer statistics, 2014. CAA
Cancer Journal for Clinicians, 64 (2), 104-117.doi: 10.3322/caac.21220.
Siegel, R.L., Miller, K.D. & Jemal, A.J. (2016). Cancer statistics 2016. CA: A Cancer

109
Journal for Clinicians, 66(1), 7-30. Doi: 10.3322/caac.21332.
Singh, M.M, Singh, E, Miller, H, Strum, W.B,& Coyle, W (2012). Colorectal cancer
screening in women with endometrial cancer: are we following the guidelines?
Journal of Gastrointestinal Cancer, 43(2),190-195. Doi: 10.1007/s12029-0119271-3.
Stone, T. W., McPherson, M., & Gail Darlington, L. (2018). Obesity and Cancer:
Existing and New Hypotheses for a Causal Connection. EBioMedicine, 30, 14–28.
Doi.org/10.1016/j.ebiom.2018.02.022
Sturmer, T., Buring, J.E., Gaziano, J.M. & Glynn, R.J. (2006). Metabolic abnormalities
and risk for colorectal cancer in the physicians’ health study. Cancer
Epidemiology Biomarkers Prevention, 15(12), 2391-2397.
Suresh, K. Thomas, S. V. & Suresh, G.(2011). Design, data analysis and sampling
techniques for clinical research. Annals of Indian Academy of Neurology, 14(4),
287–290. doi:10.4103/0972-2327.91951.
Tabuchi, M., Kitayama, J., & Nagawa, H. (2006). Hypertriglyceridemia is positively
correlated with the development of colorectal tubular adenoma in Japanese men.
World journal of gastroenterology, 12(8), 1261–1264.
https://doi.org/10.3748/wjg.v12.i8.1261
Teixeira, P. J., Carraça, E. V., Marques, M. M., Rutter, H., Oppert, J.-M., De
Bourdeaudhuij, I., … Brug, J. (2015). Successful behavior change in obesity
interventions in adults: a systematic review of self-regulation mediators. BMC
Medicine, 13, 84. http://doi.org/10.1186/s12916-015-0323-6

110
Thompson, R.H., Leibovich, B.C., Cheville, J.C., Webster, W.S., Lohse, C.M., Kwon,
E.D., ….Blute, M.L (2006). Second primary malignancies associated with renal
cell carcinoma histological subtypes. Journal of Urology,176(3), 900-903. DOI:
http://dx.doi.org/10.1016/j.juro.2006.04.080
Trabulo, D., Ribeiro, S., Martins, C., Teixeira, C., Cardoso, C., Mangualde, J., Freire.,
Gamito, E., Alves, A., Augusto, F., Oliveira, A. & Cremers, I. (2015). Metabolic
syndrome and colorectal neoplasms: An ominous association. World Journal of
Gastroenterology, 21(17), 5320–5327. doi: 10.3748/wjg.v21.i17.5320
Trabulo, D., Ribeiro, S., Martins, C., Teixeira, C., Cardoso, C., Mangualde, J. &
Cremers, I. (2015). Metabolic syndrome and colorectal neoplasms: An ominous
association. World Journal of Gastroenterology, 21(17), 5320–5327. doi:
10.3748/wjg.v21.i17.5320
Toh, E., Griffiths, B & Farooq, M (2012). An atypical presentation of colorectal cancer.
Journal of Surgical Case Reports, 1(1).2. https://doi.org/10.1093/jscr/2012.1.2
Ulmer, H., Borena, W., Rapp, K., Klenk, J., Strasak, A., Diem, G., Concin, H., & Nagel,
G. (2009). Serum triglyceride concentrations and cancer risk in a large cohort
study in Austria. British journal of cancer, 101(7), 1202–1206.
https://doi.org/10.1038/sj.bjc.6605264
Vishram, J.K.K, Borglykke, A, Andreasen, A.H, Jeppesen, J, Ibsen, H, et al. (2015)
Correction: Impact of Age and Gender on the Prevalence and Prognostic
Importance of the Metabolic Syndrome and Its Components in Europeans. PLoS
ONE,10(5): e0128848. https://doi.org/10.1371/journal.pone.0128848 View

111
correction
White, M. C., Holman, D. M., Boehm, J. E., Peipins, L. A., Grossman, M., & Henley, S.
J. (2014). Age and cancer risk: a potentially modifiable relationship. American
journal of preventive medicine, 46(3 Suppl 1), S7–S15.
https://doi.org/10.1016/j.amepre.2013.10.029
Widdison, A., Barnett, S. W., & Betambeau, N. (2011). The impact of age on outcome
after surgery for colorectal adenocarcinoma. Annals of The Royal College of
Surgeons of England, 93(6), 445–450. http://doi.org/10.1308/003588411X587154
Wishart, D.S. (2015). Is cancer a genetic disease or a metabolic disease? EBio Medicine,
2(6), 478-479. doi:10.1016/j.ebiom.2015.05.022.
Xia, X., & Cui, K. (2014). A recommendation for the management of lesions of unknown
malignancy in multiple primary malignant neoplasm patients: A case report.
Oncology Letters, 8(6),2744–2746. doi: 10.3892/ol.2014.2601
Yang, J, Li, S, Lv, M, Wu, Y, Chen, Z, Shen, Y ….. Yang, J (2017). Risk of subsequent
primary malignancies among patients with prior colorectal cancer: a populationbased cohort study. Dovepress. 10, 1535—1548.
https://doi.org/10.2147/OTT.S129220
Ye, J. (2009). Emerging Role of Adipose Tissue Hypoxia in Obesity and Insulin
Resistance. International Journal of Obesity, 33(1), 54–66.
http://doi.org/10.1038/ijo.2008.229
Yun, H.R., Yi, L.J., Cho, Y.K. (2009). Double malignancy in colorectal cancer patientsMSI is the useful marker for predicting double primary tumors. International

112
Journal of Colorectal Disease, 24,369-375. doi: 10.1007/s00384-008-0541-x.

